# Clinical trial results:
# STI571 Prospective International RandomIsed Trial 2 - A phase III, prospective randomised comparison of imatinib (STI571, Glivec/Gleevec) 400mg daily versus dasatinib (Sprycel) 100mg daily in patients with newly-diagnosed chronic phase chronic myeloid leukaemia.

## Summary

| | |
|---|---|
| EudraCT number | 2007-006185-15 |
| Trial protocol | GB |
| Global end of trial date | 07 March 2018 |

**Results information**

| | |
|---|---|
| Result version number | v1 (current) |
| This version publication date | 08 June 2019 |
| First version publication date | 08 June 2019 |

## Trial information

**Trial identification**

| | |
|---|---|
| Sponsor protocol code | SPIRIT 2 |

**Additional study identifiers**

| | |
|---|---|
| ISRCTN number | ISRCTN54923521 |
| ClinicalTrials.gov id (NCT number) | - |
| WHO universal trial number (UTN) | - |

Notes:

**Sponsors**

| | |
|---|---|
| Sponsor organisation name | Newcastle-upon-Tyne Hospitals NHS Foundation Trust |
| Sponsor organisation address | Level 1, Regent Point, Regent Farm Road, Newcastle upon Tyne, United Kingdom, NE3 3HD |
| Public contact | Professor Stephen O'Brien, Newcastle Clinical Trials Unit, 0044 0191 208 2522, stephen.o'brien@ncl.ac.uk |
| Scientific contact | Professor Stephen O'Brien, Newcastle Clinical Trials Unit, 0044 0191 208 2522, stephen.o'brien@ncl.ac.uk |

Notes:

**Paediatric regulatory details**

| | |
|---|---|
| Is trial part of an agreed paediatric investigation plan (PIP) | No |
| Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? | No |
| Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? | No |

Notes:

## Results analysis stage

| | |
|---|---|
| Analysis stage | Final |
| Date of interim/final analysis | 21 May 2018 |
| Is this the analysis of the primary completion data? | Yes |
| Primary completion date | 07 March 2018 |
| Global end of trial reached? | Yes |
| Global end of trial date | 07 March 2018 |
| Was the trial ended prematurely? | No |

Notes:

## General information about the trial

Main objective of the trial:

To compare 5-year Event Free Survival (EFS) between the two treatment arms. The study is powered to demonstrate superiority of the dasatinib arm over the imatinib arm.

Protection of trial subjects:

The study was in compliance with the ethical principles derived from the Declaration of Helsinki and the International Conference on Harmonization (ICH) Good Clinical Practice (GCP) Guidelines. All the local regulatory requirements pertinent to safety of trial subjects were also followed during the conduct of the trial.

Background therapy:

none

Evidence for comparator: -

| | |
|---|---|
| Actual start date of recruitment | 07 August 2008 |
| Long term follow-up planned | No |
| Independent data monitoring committee (IDMC) involvement? | Yes |

Notes:

## Population of trial subjects

### Subjects enrolled per country

| | |
|---|---|
| Country: Number of subjects enrolled | United Kingdom: 814 |
| Worldwide total number of subjects | 814 |
| EEA total number of subjects | 814 |

Notes:

### Subjects enrolled per age group

| | |
|---|---|
| In utero | 0 |
| Preterm newborn - gestational age < 37 wk | 0 |
| Newborns (0-27 days) | 0 |
| Infants and toddlers (28 days-23 months) | 0 |
| Children (2-11 years) | 0 |
| Adolescents (12-17 years) | 0 |
| Adults (18-64 years) | 618 |
| From 65 to 84 years | 189 |
| 85 years and over | 7 |

## Subject disposition

### Recruitment

Recruitment details:

Patients were recruited from haematology clinics in UK hospitals from August 2007 until end of February 2013. Eligible patients were screened by haematology consultants and then written informed consent obtained.

### Pre-assignment

Screening details:

Patients had blood tests (haematology and biochemistry), a bone marrow sample (aspirate and trephine) taken and a physical examination performed. Medical history and details of any concomitant diseases and any treatment given post diagnosis was noted. If patient met inclusion criteria and none of the exclusion criteria, they were then randomised.

### Period 1

| | |
|---|---|
| Period 1 title | Treatment (overall period) |
| Is this the baseline period? | Yes |
| Allocation method | Randomised - controlled |
| Blinding used | Not blinded |

### Arms

| | |
|---|---|
| Are arms mutually exclusive? | Yes |
| **Arm title** | Arm A |

Arm description:

Imatinib 400mg per day

| | |
|---|---|
| Arm type | Active comparator |
| Investigational medicinal product name | Imatinib |
| Investigational medicinal product code | |
| Other name | Glivec |
| Pharmaceutical forms | Tablet |
| Routes of administration | Oral use |

Dosage and administration details:

One 400mg tablet to be taken orally each day with water.

| | |
|---|---|
| **Arm title** | Arm B |

Arm description:

Dasatinib 100mg daily

| | |
|---|---|
| Arm type | Experimental |
| Investigational medicinal product name | Dasatinib |
| Investigational medicinal product code | |
| Other name | Sprycel |
| Pharmaceutical forms | Tablet |
| Routes of administration | Oral use |

Dosage and administration details:

One 100mg tablet to be taken once a day, orally, with water.

| **Number of subjects in period 1[1]** | Arm A | Arm B |
|---|---|---|
| Started | 406 | 406 |
| Completed | 194 | 230 |
| Not completed | 212 | 176 |
| Consent withdrawn by subject | 2 | 1 |
| Adverse event, non-fatal | 68 | 123 |
| Pregnancy | 2 | 4 |
| Patient did not want to continue first line drug | 8 | 8 |
| patient developed another concomitant condition | 4 | - |
| joined another clinical trial | - | 1 |
| developed a concomitant condition | - | 8 |
| Lost to follow-up | 4 | 3 |
| Lack of efficacy | 49 | 20 |
| Inadequate PCR response/loss of PCR response | 67 | 6 |
| patient joined another clinical trial | 7 | - |
| Protocol deviation | 1 | 2 |

Notes:

[1] - The number of subjects reported to be in the baseline period are not the same as the worldwide number enrolled in the trial. It is expected that these numbers will be the same.
Justification: Only 812 (406 in each arm), out of 814 recruited, received treatment. So all study results are based on FAS/SAF analysis population, which consists actually on 812 total patients.

## Baseline characteristics

| Reporting groups | |
|---|---|
| Reporting group title | Arm A |
| Reporting group description:<br>Imatinib 400mg per day | |
| Reporting group title | Arm B |
| Reporting group description:<br>Dasatinib 100mg daily | |

| Reporting group values | Arm A | Arm B | Total |
|---|---|---|---|
| Number of subjects | 406 | 406 | 812 |
| Age categorical<br>Units: Subjects | | | |
| Adults (18-64 years) | 309 | 308 | 617 |
| From 65-84 years | 96 | 92 | 188 |
| 85 years and over | 1 | 6 | 7 |
| Age continuous<br>Units: years | | | |
| arithmetic mean | 53.3 | 53.1 | |
| standard deviation | ± 14.7 | ± 15.4 | - |
| Gender categorical | | | |
| Male and female patients were selected from haematology clinics across the UK | | | |
| Units: Subjects | | | |
| Female | 165 | 155 | 320 |
| Male | 241 | 251 | 492 |
| Sokal Score | | | |
| prognostic indicator at baseline<br>Good prognosis (<0.8)<br>Moderate prognosis (0.8-1.2)<br>Poor prognosis (>1.2) | | | |
| Units: Subjects | | | |
| Good prognosis | 80 | 94 | 174 |
| Moderate prognosis | 86 | 78 | 164 |
| Poor prognosis | 52 | 55 | 107 |
| not recorded | 188 | 179 | 367 |
| Hasford Score | | | |
| prognostic indicator measured at baseline<br>Low risk (equal to or less than score of 780)<br>Intermediate risk (>780 to less than or equal to 1480)<br>High risk (>1480) | | | |
| Units: Subjects | | | |
| Low risk | 83 | 84 | 167 |
| Intermediate risk | 99 | 107 | 206 |
| high risk | 23 | 17 | 40 |
| not recorded | 201 | 198 | 399 |
| EUTOS Score | | | |
| Prognostic score calculated at baseline<br>Low risk (less than or equal to 87)<br>High risk (>87) | | | |
| Units: Subjects | | | |

| | | | |
|---|---|---|---|
| Low risk | 269 | 255 | 524 |
| High risk | 52 | 46 | 98 |
| Not recorded | 85 | 105 | 190 |
| ELTS Score | | | |
| EUTOS long term survival score. Prognostics score calculated at baseline<br>Low risk (less than or equal to 1.5680)<br>Intermediate risk (>1.5680 to less than or equal to 2.2185)<br>High risk (>2.2185) | | | |
| Units: Subjects | | | |
| Low risk | 122 | 133 | 255 |
| Intermediate risk | 62 | 67 | 129 |
| High risk | 34 | 27 | 61 |
| Not recorded | 188 | 179 | 367 |
| BCR-ABL transcript type | | | |
| breakpoint recorded at baseline from PCR sample | | | |
| Units: Subjects | | | |
| E13A2 | 142 | 146 | 288 |
| E14A2 | 197 | 187 | 384 |
| E13A2+E14A2 | 60 | 61 | 121 |
| E1A2 | 1 | 2 | 3 |
| not recorded | 6 | 10 | 16 |
| Time since CML diagnosis | | | |
| number of days between diagnosis and start of treatment | | | |
| Units: days | | | |
| arithmetic mean | 15 | 16 | |
| full range (min-max) | 0 to 94 | 0 to 91 | - |

**Subject analysis sets**

| | |
|---|---|
| Subject analysis set title | FAS |
| Subject analysis set type | Full analysis |

Subject analysis set description:

The FAS is defined as all randomised patients who received study medication at least once. Patients will be analysed according to the treatment group to which they were randomised, rather than by the actual treatment they were administered. The FAS is the primary population of interest for all efficacy analyses.

| | |
|---|---|
| Subject analysis set title | Safety Set |
| Subject analysis set type | Safety analysis |

Subject analysis set description:

All patients who are randomised into the study and who received study medication at least once will be considered evaluable for the Safety Set. This is the same definition as the FAS. However, in the event that a patient receives study medication other than that to which they have been randomised, analyses based on the Safety Set will be performed using the actual treatment group that was administered and so will be different to the FAS. All safety tables will be based on the Safety Set.

| **Reporting group values** | FAS | Safety Set | |
|---|---|---|---|
| Number of subjects | 812 | 812 | |
| Age categorical<br>Units: Subjects | | | |
| Adults (18-64 years) | 617 | 617 | |
| From 65-84 years | 188 | 188 | |
| 85 years and over | 7 | 7 | |

| | | | |
|---|---|---|---|
| Age continuous<br>Units: years | | | |
| arithmetic mean | 53.2 | 53.2 | |
| standard deviation | ± 15.0 | ± 15.0 | |
| Gender categorical | | | |
| Male and female patients were selected from haematology clinics across the UK | | | |
| Units: Subjects | | | |
| Female | 320 | 320 | |
| Male | 492 | 492 | |
| Sokal Score | | | |
| prognostic indicator at baseline<br>Good prognosis (<0.8)<br>Moderate prognosis (0.8-1.2)<br>Poor prognosis (>1.2) | | | |
| Units: Subjects | | | |
| Good prognosis | | | |
| Moderate prognosis | | | |
| Poor prognosis | | | |
| not recorded | | | |
| Hasford Score | | | |
| prognostic indicator measured at baseline<br>Low risk (equal to or less than score of 780)<br>Intermediate risk (>780 to less than or equal to 1480)<br>High risk (>1480) | | | |
| Units: Subjects | | | |
| Low risk | | | |
| Intermediate risk | | | |
| high risk | | | |
| not recorded | | | |
| EUTOS Score | | | |
| Prognostic score calculated at baseline<br>Low risk (less than or equal to 87)<br>High risk (>87) | | | |
| Units: Subjects | | | |
| Low risk | | | |
| High risk | | | |
| Not recorded | | | |
| ELTS Score | | | |
| EUTOS long term survival score. Prognostics score calculated at baseline<br>Low risk (less than or equal to 1.5680)<br>Intermediate risk (>1.5680 to less than or equal to 2.2185)<br>High risk (>2.2185) | | | |
| Units: Subjects | | | |
| Low risk | | | |
| Intermediate risk | | | |
| High risk | | | |
| Not recorded | | | |
| BCR-ABL transcript type | | | |
| breakpoint recorded at baseline from PCR sample | | | |
| Units: Subjects | | | |
| E13A2 | | | |
| E14A2 | | | |
| E13A2+E14A2 | | | |
| E1A2 | | | |
| not recorded | | | |

| | | | |
|---|---|---|---|
| Time since CML diagnosis | | | |
| number of days between diagnosis and start of treatment | | | |
| Units: days<br>arithmetic mean<br>full range (min-max) | | | |

## End points

### End points reporting groups

| | |
|---|---|
| Reporting group title | Arm A |
| Reporting group description: Imatinib 400mg per day | |
| Reporting group title | Arm B |
| Reporting group description: Dasatinib 100mg daily | |
| Subject analysis set title | FAS |
| Subject analysis set type | Full analysis |

Subject analysis set description:

The FAS is defined as all randomised patients who received study medication at least once. Patients will be analysed according to the treatment group to which they were randomised, rather than by the actual treatment they were administered. The FAS is the primary population of interest for all efficacy analyses.

| | |
|---|---|
| Subject analysis set title | Safety Set |
| Subject analysis set type | Safety analysis |

Subject analysis set description:

All patients who are randomised into the study and who received study medication at least once will be considered evaluable for the Safety Set. This is the same definition as the FAS. However, in the event that a patient receives study medication other than that to which they have been randomised, analyses based on the Safety Set will be performed using the actual treatment group that was administered and so will be different to the FAS. All safety tables will be based on the Safety Set.

### Primary: Event free survival at 5 years

| | |
|---|---|
| End point title | Event free survival at 5 years |

End point description:

To establish whether dasatinib is superior to imatinib in terms of event free survival censored at 5 years. An event includes death from any cause, disease progression, loss of complete haematological response (CHR), increasing white blood cell count, or loss of major cytogenetic response (MCR).

| | |
|---|---|
| End point type | Primary |

End point timeframe:

5 years

| End point values | Arm A | Arm B | | |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 406 | 406 | | |
| Units: number of patients | | | | |
| Death: non CML related | 23 | 21 | | |
| Death: CML related | 2 | 0 | | |
| Disease progression - blast crisis | 7 | 6 | | |
| disease progression - accelerated phase | 4 | 4 | | |
| Loss of CHR | 5 | 3 | | |
| Loss of MCR | 2 | 1 | | |
| Increasing white blood cell count | 0 | 0 | | |
| No event | 363 | 371 | | |

| | |
|---|---|
| **Attachments (see zip file)** | Kaplan-Meier Plot of Event Free Survival/KM_Overall.png |

### Statistical analyses

| | |
|---|---|
| **Statistical analysis title** | Event-Free Survival Kaplan-Meier Analysis |

Statistical analysis description:

An event includes: death (any cause), disease progression, loss of CHR, increase in WBC count, or loss of MCR. See protocol for full details.
Event-free survival is calculated as (Date of event - Date of first dose of study medication)/30.4.
Patients who have not experienced an event within 5 years are censored at the earliest of (date of last visit, or the date of first dose of study medication + 1826.25 days).

| | |
|---|---|
| Comparison groups | Arm B v Arm A |
| Number of subjects included in analysis | 812 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | = 0.318 |
| Method | Logrank |

| | |
|---|---|
| **Statistical analysis title** | Event-Free Survival Cox Proportional Hazard Model |

Statistical analysis description:

An event includes: death (any cause), disease progression, loss of CHR, increase in WBC count, or loss of MCR. See protocol for full details.
Event-free survival is calculated as (Date of event - Date of first dose of study medication)/30.4.
Patients who have not experienced an event within 5 years are censored at the earliest of (Date of last visit, or the date of first dose of study medication + 1826.25 days).

| | |
|---|---|
| Comparison groups | Arm B v Arm A |
| Number of subjects included in analysis | 812 |
| Analysis specification | Pre-specified |
| Analysis type | superiority[1] |
| P-value | = 0.319 |
| Method | Regression, Cox |
| Parameter estimate | Hazard ratio (HR) |
| Point estimate | 0.797 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | 0.51 |
| upper limit | 1.245 |

Notes:

[1] - Analysis is based on a Cox proportional hazards model with treatment group included as an explanatory variable.

| | |
|---|---|
| **Statistical analysis title** | Sensitivity Analysis |

Statistical analysis description:

Event-Free Survival Cox Proportional Hazards Model (Sensitivity Analysis)
An event includes: death (any cause), disease progression, loss of CHR, increase in WBC count, or loss of MCR. See protocol for full details.
Event-free survival is calculated as (Date of event - Date of first dose of study medication)/30.4.
Patients who have not experienced an event within 5 years are censored at the earliest of (Date of last visit, or the date of first dose of study medication + 1826.25 days).

| | |
|---|---|
| Comparison groups | Arm B v Arm A |
| Number of subjects included in analysis | 812 |
| Analysis specification | Pre-specified |
| Analysis type | superiority[2] |
| P-value | = 0.216 |
| Method | Regression, Cox |
| Parameter estimate | Cox proportional hazard |
| Point estimate | 0.75 |
| Confidence interval | |
| level | 95 % |
| sides | 2-sided |
| lower limit | 0.476 |
| upper limit | 1.183 |

Notes:

[2] - Analysis is based on a Cox proportional hazards model with treatment group, gender, BCR-ABL transcript, dose received in first 3 months (<90% or =90%) included as explanatory variables.

## Secondary: Rate of complete cytogenetic response

| | |
|---|---|
| End point title | Rate of complete cytogenetic response |

End point description:

The proportion of patients achieving CCR according to the G banding .
For G-banding: CCR is defined as 0% Philadelphia chromosome positive metaphases in bone marrow cells.
Data is presented as observed and worst case data where worst case presumes patients with missing cytogenetic responses are non-responders. Worst case data is presented as attachment.

| | |
|---|---|
| End point type | Secondary |

End point timeframe:

24 months

| End point values | Arm A | Arm B | | |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 406 | 406 | | |
| Units: number of patients | | | | |
| Yes | 129 | 173 | | |
| No | 28 | 27 | | |
| not evaluable | 249 | 206 | | |

| | |
|---|---|
| **Attachments (see zip file)** | Complete cytogenetic response by G-banding - worst case |

## Statistical analyses

| Statistical analysis title | Complete Cytogenetic Response(CCR) (Observed Data) |
|---|---|
| Comparison groups | Arm B v Arm A |
| Number of subjects included in analysis | 812 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | = 0.26 |
| Method | Chi-squared |

## Secondary: Rate of treatment failure

| End point title | Rate of treatment failure |
|---|---|

End point description:

Treatment failure includes all events, intolerance (such that the patient has to stop study drug permanently) , failure to achieve complete haematological response (CHR) after 6 months of treatment, failure to achieve major cytogenetic response (MCR) after 12 months of treatment, failure to achieve CCR after 24 months of treatment, failure to achieve adequate PCR (defined as >10% after 3 months treatment, >1% after 6 months treatment and >0/1% after 12 months treatment) and loss of adequate PCR response (as assessed by investigator).

| End point type | Secondary |
|---|---|

End point timeframe:

5 years

| End point values | Arm A | Arm B | | |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 406 | 406 | | |
| Units: Number of patients | | | | |
| Death: non CML related | 14 | 12 | | |
| Death: CML related | 0 | 0 | | |
| Disease progression - blast crisis | 7 | 4 | | |
| Disease progression - accelerated phase | 0 | 4 | | |
| Loss of CHR | 4 | 0 | | |
| Loss of MCR | 2 | 1 | | |
| increasing WBC count | 0 | 0 | | |
| Intolerance | 69 | 120 | | |
| Failure to achieve CHR after 6 mths of treatment | 1 | 0 | | |
| Failure to achieve MCR after 12 months of treatmen | 16 | 7 | | |
| Failure to achieve CCR after 24 mths of treatment | 10 | 1 | | |
| Failure to achieve adequate PCR | 54 | 6 | | |
| Loss of adequate PCR response | 12 | 1 | | |
| No treatment failure | 217 | 250 | | |

| Attachments (see zip file) | TIME TO TREATMENT FAILURE KAPLAN-MEIER |
|---|---|

**Statistical analyses**

| **Statistical analysis title** | Time to Treatment Failure Kaplan-Meier Analysis |
|---|---|

Statistical analysis description:

Time to treatment failure is calculated as (Date of failure - Date of first dose of study medication)/30.4. Patients who have not experienced treatment failure at 5 years are censored at the earliest of (date of last visit, or the date of first dose of study medication + 1826.25 days).

| | |
|---|---|
| Comparison groups | Arm B v Arm A |
| Number of subjects included in analysis | 812 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | = 0.004 |
| Method | Logrank |

**Secondary: Rate of complete haematological response**

| End point title | Rate of complete haematological response |
|---|---|

End point description:

To compare the dates of complete haematological response (CHR) in patients on each arm after 6 months of treatment. Patients were not evaluable if the data was missing at the timepoint required. Data were analysed as observed data and worst cases data where worst case presumes patients with a missing response are non-responders.

| End point type | Secondary |
|---|---|

End point timeframe:

6 months

| **End point values** | Arm A | Arm B | | |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 406 | 406 | | |
| Units: number of patients | | | | |
| yes | 371 | 378 | | |
| no | 22 | 5 | | |
| not evaluable | 13 | 23 | | |

| **Attachments (see zip file)** | Complete haematological response (worst case data).pdf |
|---|---|

**Statistical analyses**

| **Statistical analysis title** | Complete Haematologic Response(CHR)(Observed Data) |
|---|---|

Statistical analysis description:

Duration of CHR calculated as (earliest of (Date of loss of CHR, or date of treatment failure) - Date of first documentation of CHR)/30.4.

| Comparison groups | Arm B v Arm A |
|---|---|

| | |
|---|---|
| Number of subjects included in analysis | 812 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | = 0.001 |
| Method | Chi-squared |

## Secondary: Level of molecular responses by PCR on first line therapy

| | |
|---|---|
| End point title | Level of molecular responses by PCR on first line therapy |

End point description:

The level of molecular responses (BCR-ABL/ABL ratio by real time polymerase chain reaction (international scale) (PCR) in each of the treatment arms.

| | |
|---|---|
| End point type | Secondary |

End point timeframe:

MR1 (<10% )at 3 months, MR2 (<1%) at 6 months, MR3 (<0.1%) at 12 months, MR4.5 (<0.032) at any time

| End point values | Arm A | Arm B | | |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 406 | 406 | | |
| Units: number of patients | | | | |
| MR1 yes | 264 | 305 | | |
| MR1 no | 115 | 84 | | |
| not evaluable for MR1 | 27 | 17 | | |
| MR2 yes | 202 | 277 | | |
| MR2 no | 113 | 90 | | |
| not evaluable for MR2 | 91 | 39 | | |
| MR3 yes | 181 | 252 | | |
| MR3 no | 92 | 100 | | |
| not evaluable for MR3 | 133 | 54 | | |
| MR4.5 yes | 231 | 313 | | |
| MR4.5 no | 31 | 27 | | |
| not evaluable for MR4 | 144 | 66 | | |

### Statistical analyses

No statistical analyses for this end point

## Secondary: Quality of Life

| | |
|---|---|
| End point title | Quality of Life |

End point description:

Quality of life was assessed between the 2 arms. EQ-5D, FACT-G and FACT-BRM questionnaires were completed by patients during clinic visits. Data is presented graphically in attachment.

| | |
|---|---|
| End point type | Secondary |

End point timeframe:

baseline, 3 months, 6, months, 9 months, 12 months, 18 months, 24 months, 30 months, 36 months, 42 months, 48 months, 54 months, 60 months

| **End point values** | FAS | | | |
|---|---|---|---|---|
| Subject group type | Subject analysis set | | | |
| Number of subjects analysed | | | | |
| Units: percentage | 812 | | | |

| **Attachments (see zip file)** | Quality of Life data in figures.pdf |
|---|---|

### Statistical analyses

No statistical analyses for this end point

### Secondary: Overall survival

| End point title | Overall survival |
|---|---|

End point description:

Death from any cause was considered. Overall survival censored at 2 years (24 months) and 5 years (60 months) will be compared across treatments. Data is presented for 5 years and 2 years in attachment.

| End point type | Secondary |
|---|---|

End point timeframe:

2 years and 5 years

| **End point values** | Arm A | Arm B | | |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 406 | 406 | | |
| Units: number of events (deaths) | | | | |
| 0-12 months | 5 | 5 | | |
| 12-24 months | 11 | 9 | | |
| 24-36 months | 19 | 14 | | |
| 36-48 months | 27 | 25 | | |
| 48 to 60 months | 34 | 31 | | |

| **Attachments (see zip file)** | Overall survival at 2 years.pdf |
|---|---|

### Statistical analyses

No statistical analyses for this end point

## Secondary: Tolerability between the regimens

| End point title | Tolerability between the regimens |
|---|---|

End point description:

The assessment of tolerability will consist of evaluating adverse events, laboratory parameters including haematology (haemaglobin, % blasts, WBC count, platelet count) and biochemistry (total bilirubin, LDH, AST, ALT, alkaline phosphatase, creatinine and urea), physical examinations and documentation of all concomitant medications and/or therapies including blood products. C'ardiovascular AEs include AEs with a preferred term of 'myocardial infarction', 'acute myocardial infarction', 'angina pectoris', 'coronary artery disease', 'acute coronary syndrome. Cytopenia AEs include AEs with a preferred term of 'anaemia', 'neutropenia' or 'thrombocytopenia'.

| End point type | Secondary |
|---|---|

End point timeframe:

From start of study medication to 30 days after study medication stopped for each patient

| End point values | Arm A | Arm B | | |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 406 | 406 | | |
| Units: number of patients | | | | |
| Number of AEs | 3801 | 4882 | | |
| Number of patients with AEs | 398 | 402 | | |
| Number of SAEs | 275 | 536 | | |
| Number of patients with SAEs | 140 | 233 | | |
| Number of ADRs | 1554 | 1861 | | |
| Number of patients with ADRs | 360 | 364 | | |
| Number of serious ADRs | 40 | 151 | | |
| Number of patients with serious ADRs | 33 | 105 | | |
| Number of pleural effusion events | 6 | 260 | | |
| No. of patients with pleural effusion events | 6 | 146 | | |
| Number of pulmonary arterial hypertension events | 0 | 1 | | |
| No. of pts with PAH events | 0 | 1 | | |
| Number of dyspnoea events | 41 | 141 | | |
| Number of patients with dyspnoea events | 38 | 100 | | |
| Number of cardiovascular AEs | 4 | 14 | | |
| Number of patients with cardiovascular AEs | 4 | 12 | | |
| Number of cytopenia AEs | 127 | 272 | | |
| Number of patients with cytopenia AEs | 76 | 129 | | |
| Number of severe AEs | 166 | 289 | | |
| Number of patients with severe AEs | 109 | 156 | | |
| Number of AEs with tox grade 3 or 4 | 325 | 587 | | |
| No. of patients with AEs of tox grade 3 or 4 | 185 | 253 | | |
| Number of AEs leading to discontinuation | 126 | 175 | | |
| No. of pts with AEs leading to discontinuation | 89 | 149 | | |
| Number of AEs leading to death | 22 | 18 | | |
| Number of patients with AEs leading to death | 20 | 18 | | |

| | |
|---|---|
| **Attachments (see zip file)** | Uncoded AEs/S2 - AEs not able to be coded in MEDDRA Feb |

## Statistical analyses

No statistical analyses for this end point

## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

Occurring after starting study drug and up to 30 days after last dose

Adverse event reporting additional description:

Adverse events (AEs) collected by physician, reported by patient or from laboratory tests. AEs were defined as any undesirable sign, symptom or medical condition whether considered study drug-related or not. If present before starting study drug, they are only considered AEs if they worsen after starting study drug.

| | |
|---|---|
| Assessment type | Non-systematic |

### Dictionary used

| | |
|---|---|
| Dictionary name | MedDRA |
| Dictionary version | 20 |

### Reporting groups

| | |
|---|---|
| Reporting group title | Imatinib 400mg daily |

Reporting group description:

Imatinib 400mg daily

| | |
|---|---|
| Reporting group title | Dasatinib 100mg daily |

Reporting group description:

Dasatinib 100mg daily

| Serious adverse events | Imatinib 400mg daily | Dasatinib 100mg daily | |
|---|---|---|---|
| Total subjects affected by serious adverse events | | | |
| subjects affected / exposed | 141 / 406 (34.73%) | 234 / 406 (57.64%) | |
| number of deaths (all causes) | 34 | 31 | |
| number of deaths resulting from adverse events | 20 | 18 | |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | | | |
| ACUTE LYMPHOCYTIC LEUKAEMIA | | | |
| subjects affected / exposed | 2 / 406 (0.49%) | 0 / 406 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | |
| ACUTE MYELOID LEUKAEMIA | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 3 / 406 (0.74%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 3 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 3 | |
| ADENOCARCINOMA | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |

| | | | |
|---|---|---|---|
| B PRECURSOR TYPE ACUTE LEUKAEMIA | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| B-CELL LYMPHOMA | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| BASAL CELL CARCINOMA | | | |
| subjects affected / exposed | 3 / 406 (0.74%) | 5 / 406 (1.23%) | |
| occurrences causally related to treatment / all | 0 / 3 | 0 / 5 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| BLADDER TRANSITIONAL CELL CARCINOMA | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| BLAST CELL CRISIS | | | |
| subjects affected / exposed | 2 / 406 (0.49%) | 1 / 406 (0.25%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 1 | 0 / 1 | |
| BLAST CRISIS IN MYELOGENOUS LEUKAEMIA | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | |
| BREAST CANCER | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 2 / 406 (0.49%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | |
| CHOLANGIOCARCINOMA | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | |

| | | | |
|---|---|---|---|
| CHRONIC MYELOID LEUKAEMIA | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| COLON CANCER | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| DIFFUSE LARGE B-CELL LYMPHOMA | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| ENDOMETRIAL CANCER | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| ENDOMETRIAL CANCER METASTATIC | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | |
| FOCAL NODULAR HYPERPLASIA | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| GASTRIC CANCER | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | |
| INTRADUCTAL PROLIFERATIVE BREAST LESION | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| KERATOACANTHOMA | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| LUNG ADENOCARCINOMA | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 1 / 406 (0.25%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 1 | 0 / 1 | |
| LYMPHOMA | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | |
| MALIGNANT NEOPLASM PROGRESSION | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | |
| MENINGIOMA | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| MENINGIOMA MALIGNANT | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| METASTASES TO RECTUM | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | |
| METASTASIS | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| MYELODYSPLASTIC SYNDROME | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| PARATHYROID TUMOUR BENIGN | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| PLASMA CELL MYELOMA | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| PROSTATE CANCER | | | |
| subjects affected / exposed | 4 / 406 (0.99%) | 0 / 406 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 4 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| RECTAL ADENOMA | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| RENAL CANCER | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| RENAL ONCOCYTOMA | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| SQUAMOUS CELL CARCINOMA | | | |
| subjects affected / exposed | 2 / 406 (0.49%) | 1 / 406 (0.25%) | |
| occurrences causally related to treatment / all | 0 / 3 | 1 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| SQUAMOUS CELL CARCINOMA OF LUNG | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 406 (0.00%) | 2 / 406 (0.49%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | |
| TERATOMA | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| UTERINE LEIOMYOMA | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 2 / 406 (0.49%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Vascular disorders | | | |
| AORTIC ANEURYSM | | | |
| subjects affected / exposed | 2 / 406 (0.49%) | 0 / 406 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | |
| AORTIC STENOSIS | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 1 / 406 (0.25%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| ARTERIAL STENOSIS | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| DEEP VEIN THROMBOSIS | | | |
| subjects affected / exposed | 4 / 406 (0.99%) | 1 / 406 (0.25%) | |
| occurrences causally related to treatment / all | 0 / 4 | 1 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| HAEMATOMA | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 1 / 406 (0.25%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| HAEMORRHAGE | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| HYPERTENSION | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| HYPOTENSION | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | |
| INTERMITTENT CLAUDICATION | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| INTERNAL HAEMORRHAGE | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| LYMPHOEDEMA | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| PERIPHERAL ARTERY OCCLUSION | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| PERIPHERAL ISCHAEMIA | | | |
| subjects affected / exposed | 2 / 406 (0.49%) | 0 / 406 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| THROMBOSIS | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| VASODILATATION | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Surgical and medical procedures | | | |
| BREAST OPERATION | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| CHOLECYSTECTOMY | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 1 / 406 (0.25%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| HERNIA REPAIR | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| HIP ARTHROPLASTY | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| JOINT DEBRIDEMENT | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| General disorders and administration site conditions | | | |
| ADVERSE DRUG REACTION | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences causally related to treatment / all | 0 / 0 | 1 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |

| | | | |
|---|---|---|---|
| CATHETER SITE EXTRAVASATION | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| CATHETER SITE HAEMORRHAGE | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| CHEST PAIN | | | |
| subjects affected / exposed | 2 / 406 (0.49%) | 10 / 406 (2.46%) | |
| occurrences causally related to treatment / all | 0 / 2 | 2 / 10 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| DISEASE PROGRESSION | | | |
| subjects affected / exposed | 3 / 406 (0.74%) | 2 / 406 (0.49%) | |
| occurrences causally related to treatment / all | 1 / 3 | 1 / 2 | |
| deaths causally related to treatment / all | 0 / 2 | 0 / 0 | |
| GENERAL PHYSICAL HEALTH DETERIORATION | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| GENERALISED OEDEMA | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| INFLUENZA LIKE ILLNESS | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 3 / 406 (0.74%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 3 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| MUCOSAL ULCERATION | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| NON-CARDIAC CHEST PAIN | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| OEDEMA | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences causally related to treatment / all | 0 / 0 | 1 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| OEDEMA PERIPHERAL | | | |
| subjects affected / exposed | 3 / 406 (0.74%) | 1 / 406 (0.25%) | |
| occurrences causally related to treatment / all | 3 / 3 | 1 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| PAIN | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| PERIPHERAL SWELLING | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 2 / 406 (0.49%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| PYREXIA | | | |
| subjects affected / exposed | 3 / 406 (0.74%) | 12 / 406 (2.96%) | |
| occurrences causally related to treatment / all | 1 / 3 | 6 / 13 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Immune system disorders | | | |
| ANAPHYLACTIC REACTION | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| DRUG HYPERSENSITIVITY | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 1 / 406 (0.25%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| HYPERSENSITIVITY | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 1 / 406 (0.25%) | 1 / 406 (0.25%) | |
| occurrences causally related to treatment / all | 0 / 1 | 1 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Reproductive system and breast disorders | | | |
| DYSMENORRHOEA | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| MENORRHAGIA | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| OEDEMA GENITAL | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| PRIAPISM | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 3 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| TESTICULAR SWELLING | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Respiratory, thoracic and mediastinal disorders | | | |
| ASTHMA | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 4 / 406 (0.99%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 4 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| CHRONIC OBSTRUCTIVE PULMONARY DISEASE | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 2 / 406 (0.49%) | 3 / 406 (0.74%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 4 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| COUGH | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| DYSPHONIA | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| DYSPNOEA | | | |
| subjects affected / exposed | 3 / 406 (0.74%) | 7 / 406 (1.72%) | |
| occurrences causally related to treatment / all | 0 / 3 | 3 / 8 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| EMPHYSEMA | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| EPISTAXIS | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| HAEMOPTYSIS | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| HAEMOTHORAX | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| HYPOXIA | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| OROPHARYNGEAL PAIN | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences causally related to treatment / all | 0 / 0 | 1 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| PLEURAL EFFUSION | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 56 / 406 (13.79%) | |
| occurrences causally related to treatment / all | 0 / 1 | 61 / 65 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| PLEURITIC PAIN | | | |
| subjects affected / exposed | 2 / 406 (0.49%) | 0 / 406 (0.00%) | |
| occurrences causally related to treatment / all | 1 / 2 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| PNEUMONITIS | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| PULMONARY ARTERIAL HYPERTENSION | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences causally related to treatment / all | 0 / 0 | 1 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| PULMONARY CONGESTION | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences causally related to treatment / all | 0 / 0 | 1 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| PULMONARY EMBOLISM | | | |
| subjects affected / exposed | 2 / 406 (0.49%) | 2 / 406 (0.49%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| PULMONARY HYPERTENSION | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 406 (0.00%) | 4 / 406 (0.99%) | |
| occurrences causally related to treatment / all | 0 / 0 | 4 / 4 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| PULMONARY OEDEMA | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences causally related to treatment / all | 0 / 0 | 1 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Psychiatric disorders | | | |
| CONFUSIONAL STATE | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 2 / 406 (0.49%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | |
| DEPRESSION | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 1 / 406 (0.25%) | |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| MAJOR DEPRESSION | | | |
| subjects affected / exposed | 2 / 406 (0.49%) | 1 / 406 (0.25%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| MENTAL DISORDER | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | |
| occurrences causally related to treatment / all | 2 / 2 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| PSYCHOTIC DISORDER | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| SUICIDE ATTEMPT | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Investigations | | | |

| | | | |
|---|---|---|---|
| ALANINE AMINOTRANSFERASE INCREASED | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| BLOOD CREATININE INCREASED | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| BLOOD UREA INCREASED | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| ELECTROCARDIOGRAM QT PROLONGED | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 1 / 406 (0.25%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| ELECTROCARDIOGRAM ST-T SEGMENT ABNORMAL | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences causally related to treatment / all | 0 / 0 | 1 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| GAMMA-GLUTAMYLTRANSFERASE INCREASED | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| HAEMOGLOBIN DECREASED | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences causally related to treatment / all | 0 / 0 | 1 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| LIVER FUNCTION TEST INCREASED | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |

| | | | |
|---|---|---|---|
| Injury, poisoning and procedural complications | | | |
| ACCIDENTAL OVERDOSE | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| ANKLE FRACTURE | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| CATARACT OPERATION COMPLICATION | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| FACIAL BONES FRACTURE | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 6 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| FALL | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 2 / 406 (0.49%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 3 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| HUMERUS FRACTURE | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 1 / 406 (0.25%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| INJURY | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| INTENTIONAL OVERDOSE | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |

| | | | |
|---|---|---|---|
| JOINT DISLOCATION | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| JOINT INJURY | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| LACERATION | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| LUMBAR VERTEBRAL FRACTURE | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| OPEN FRACTURE | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| POST PROCEDURAL COMPLICATION | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| POST PROCEDURAL HAEMORRHAGE | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| RIB FRACTURE | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| SOFT TISSUE INJURY | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| STERNAL FRACTURE | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| SUBARACHNOID HAEMORRHAGE | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 2 / 406 (0.49%) | |
| occurrences causally related to treatment / all | 0 / 0 | 1 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| SUBDURAL HAEMORRHAGE | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 2 / 406 (0.49%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| SYNOVIAL RUPTURE | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| TRANSFUSION REACTION | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| UPPER LIMB FRACTURE | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Congenital, familial and genetic disorders | | | |
| ATRIAL SEPTAL DEFECT | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| ICHTHYOSIS | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Cardiac disorders | | | |
| ACUTE CORONARY SYNDROME | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 2 / 406 (0.49%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | |
| ACUTE MYOCARDIAL INFARCTION | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 3 / 406 (0.74%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 3 | |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | |
| AGONAL RHYTHM | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | |
| ANGINA PECTORIS | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 2 / 406 (0.49%) | |
| occurrences causally related to treatment / all | 0 / 0 | 1 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| ARRHYTHMIA | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 1 / 406 (0.25%) | |
| occurrences causally related to treatment / all | 0 / 1 | 1 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| ATRIAL FIBRILLATION | | | |
| subjects affected / exposed | 7 / 406 (1.72%) | 3 / 406 (0.74%) | |
| occurrences causally related to treatment / all | 0 / 9 | 1 / 5 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| ATRIAL FLUTTER | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences causally related to treatment / all | 0 / 0 | 1 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| ATRIOVENTRICULAR BLOCK | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences causally related to treatment / all | 0 / 0 | 1 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| ATRIOVENTRICULAR BLOCK FIRST DEGREE | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| BRADYCARDIA | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| CARDIAC ARREST | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | |
| CARDIAC FAILURE | | | |
| subjects affected / exposed | 4 / 406 (0.99%) | 4 / 406 (0.99%) | |
| occurrences causally related to treatment / all | 0 / 4 | 2 / 5 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 2 | |
| CARDIAC FAILURE CONGESTIVE | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 1 / 406 (0.25%) | |
| occurrences causally related to treatment / all | 1 / 1 | 2 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| CARDIAC TAMPONADE | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences causally related to treatment / all | 0 / 0 | 1 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| CARDIOMEGALY | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences causally related to treatment / all | 0 / 0 | 1 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| CORONARY ARTERY DISEASE | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| CYANOSIS | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | |
| LEFT VENTRICULAR FAILURE | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences causally related to treatment / all | 0 / 0 | 1 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| MYOCARDIAL INFARCTION | | | |
| subjects affected / exposed | 2 / 406 (0.49%) | 2 / 406 (0.49%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| MYOCARDIAL ISCHAEMIA | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 3 / 406 (0.74%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 3 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| PALPITATIONS | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 2 / 406 (0.49%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| PERICARDIAL EFFUSION | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 5 / 406 (1.23%) | |
| occurrences causally related to treatment / all | 0 / 0 | 5 / 5 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| PERICARDITIS | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences causally related to treatment / all | 0 / 0 | 1 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| SUPRAVENTRICULAR TACHYCARDIA | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Nervous system disorders | | | |
| AMNESIA | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| BALANCE DISORDER | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| CENTRAL NERVOUS SYSTEM HAEMORRHAGE | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | |
| CEREBELLAR HAEMORRHAGE | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| CEREBRAL INFARCTION | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| CEREBROVASCULAR ACCIDENT | | | |
| subjects affected / exposed | 2 / 406 (0.49%) | 3 / 406 (0.74%) | |
| occurrences causally related to treatment / all | 0 / 2 | 1 / 3 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | |
| DIZZINESS | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 2 / 406 (0.49%) | |
| occurrences causally related to treatment / all | 0 / 0 | 1 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| HEADACHE | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 1 / 406 (0.25%) | 2 / 406 (0.49%) | |
| occurrences causally related to treatment / all | 0 / 1 | 1 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| ISCHAEMIC STROKE | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| LACUNAR INFARCTION | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| LOSS OF CONSCIOUSNESS | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| MIGRAINE | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences causally related to treatment / all | 0 / 0 | 1 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| NEUROPATHY PERIPHERAL | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| OPTIC NEURITIS | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| PERIPHERAL SENSORY NEUROPATHY | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences causally related to treatment / all | 0 / 0 | 1 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| PRESYNCOPE | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| SEIZURE | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| SOMNOLENCE | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| SPEECH DISORDER | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| SYNCOPE | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 1 / 406 (0.25%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| TRANSIENT ISCHAEMIC ATTACK | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Blood and lymphatic system disorders | | | |
| ANAEMIA | | | |
| subjects affected / exposed | 2 / 406 (0.49%) | 4 / 406 (0.99%) | |
| occurrences causally related to treatment / all | 2 / 2 | 2 / 4 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| CYTOPENIA | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences causally related to treatment / all | 0 / 0 | 1 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| LYMPHADENOPATHY | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| NEUTROPENIA | | | |
| subjects affected / exposed | 3 / 406 (0.74%) | 1 / 406 (0.25%) | |
| occurrences causally related to treatment / all | 3 / 3 | 1 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| THROMBOCYTOPENIA | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences causally related to treatment / all | 0 / 0 | 1 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| THROMBOCYTOSIS | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Ear and labyrinth disorders | | | |
| MENIERE'S DISEASE | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| MIDDLE EAR EFFUSION | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| VERTIGO POSITIONAL | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Eye disorders | | | |
| CORNEAL PERFORATION | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| EYE OEDEMA | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| EYE SWELLING | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| MACULAR DEGENERATION | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| PERIORBITAL OEDEMA | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| RETINAL DETACHMENT | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| VITREOUS HAEMORRHAGE | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Gastrointestinal disorders | | | |
| ABDOMINAL HERNIA | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| ABDOMINAL HERNIA OBSTRUCTIVE | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| ABDOMINAL PAIN | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 2 / 406 (0.49%) | 6 / 406 (1.48%) | |
| occurrences causally related to treatment / all | 0 / 2 | 1 / 6 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| ABDOMINAL PAIN LOWER | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 1 / 406 (0.25%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| ABDOMINAL PAIN UPPER | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences causally related to treatment / all | 0 / 0 | 1 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| ANAL FISSURE | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| ASCITES | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 2 / 406 (0.49%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 4 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| BARRETT'S OESOPHAGUS | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| COLITIS | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 2 / 406 (0.49%) | |
| occurrences causally related to treatment / all | 0 / 0 | 2 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| CONSTIPATION | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| CROHN'S DISEASE | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| DIARRHOEA | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 9 / 406 (2.22%) | |
| occurrences causally related to treatment / all | 0 / 1 | 4 / 11 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| DIVERTICULUM | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| DUODENAL STENOSIS | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| DYSPHAGIA | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| ENTEROCUTANEOUS FISTULA | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| EPIGASTRIC DISCOMFORT | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| EROSIVE DUODENITIS | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| GASTRIC MUCOSAL LESION | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| GASTRIC ULCER | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| GASTRITIS | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 2 / 406 (0.49%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| GASTROINTESTINAL HAEMORRHAGE | | | |
| subjects affected / exposed | 2 / 406 (0.49%) | 0 / 406 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 1 | 0 / 0 | |
| HAEMATEMESIS | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| INTESTINAL OBSTRUCTION | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| INTESTINAL PERFORATION | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| LARGE INTESTINAL OBSTRUCTION | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| LARGE INTESTINAL STENOSIS | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| LARGE INTESTINE PERFORATION | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| NAUSEA | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences causally related to treatment / all | 0 / 0 | 1 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| PANCREATITIS ACUTE | | | |
| subjects affected / exposed | 2 / 406 (0.49%) | 0 / 406 (0.00%) | |
| occurrences causally related to treatment / all | 1 / 2 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| RECTAL HAEMORRHAGE | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 1 / 406 (0.25%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| SMALL INTESTINAL OBSTRUCTION | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| VOMITING | | | |
| subjects affected / exposed | 2 / 406 (0.49%) | 5 / 406 (1.23%) | |
| occurrences causally related to treatment / all | 1 / 2 | 0 / 6 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Hepatobiliary disorders | | | |
| BILIARY COLIC | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| CHOLECYSTITIS | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 1 / 406 (0.25%) | 2 / 406 (0.49%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 3 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| GALLBLADDER PAIN | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| HEPATIC CIRRHOSIS | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 2 / 406 (0.49%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 2 | |
| **Skin and subcutaneous tissue disorders** | | | |
| ANGIOEDEMA | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 1 / 406 (0.25%) | |
| occurrences causally related to treatment / all | 0 / 1 | 1 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| ERYTHEMA MULTIFORME | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| HYPERSENSITIVITY VASCULITIS | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| PERIVASCULAR DERMATITIS | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences causally related to treatment / all | 0 / 0 | 1 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| RASH | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| RASH MACULAR | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| SKIN REACTION | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| SWELLING FACE | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| VASCULITIC RASH | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 1 / 406 (0.25%) | |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Renal and urinary disorders | | | |
| ACUTE KIDNEY INJURY | | | |
| subjects affected / exposed | 2 / 406 (0.49%) | 4 / 406 (0.99%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 4 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| HAEMATURIA | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 2 / 406 (0.49%) | |
| occurrences causally related to treatment / all | 0 / 0 | 3 / 4 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| NEPHROLITHIASIS | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 1 / 406 (0.25%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| NEPHROTIC SYNDROME | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences causally related to treatment / all | 0 / 0 | 1 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| POLLAKIURIA | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| URETHRAL DISORDER | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| URETHRAL STENOSIS | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| URINARY RETENTION | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 2 / 406 (0.49%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 3 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Endocrine disorders | | | |
| HYPERTHYROIDISM | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences causally related to treatment / all | 0 / 0 | 1 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| THYROID MASS | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Musculoskeletal and connective tissue disorders | | | |
| ARTHRALGIA | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 3 / 406 (0.74%) | |
| occurrences causally related to treatment / all | 0 / 1 | 1 / 3 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |

| | | | |
|---|---|---|---|
| ARTHRITIS | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| BACK PAIN | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 4 / 406 (0.99%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 4 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| BONE EROSION | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| BONE INFARCTION | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| COSTOCHONDRITIS | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| FLANK PAIN | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| FRACTURE NONUNION | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| GROIN PAIN | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 1 / 406 (0.25%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| HAEMARTHROSIS | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 2 / 406 (0.49%) | 0 / 406 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| INTERVERTEBRAL DISC PROTRUSION | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 2 / 406 (0.49%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| MOBILITY DECREASED | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| MUSCULAR WEAKNESS | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| MUSCULOSKELETAL PAIN | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 1 / 406 (0.25%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| MYALGIA | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 2 / 406 (0.49%) | |
| occurrences causally related to treatment / all | 0 / 0 | 2 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| NECK PAIN | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| OSTEITIS DEFORMANS | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 1 / 406 (0.25%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| OSTEOARTHRITIS | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 4 / 406 (0.99%) | 2 / 406 (0.49%) | |
| occurrences causally related to treatment / all | 0 / 6 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| OSTEONECROSIS | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 1 / 406 (0.25%) | |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| PAIN IN EXTREMITY | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| PERIARTHRITIS | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| ROTATOR CUFF SYNDROME | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| SPINAL OSTEOARTHRITIS | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| SPINAL PAIN | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| SYNOVITIS | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Infections and infestations | | | |
| ABSCESS LIMB | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| ANAL ABSCESS | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| APPENDICITIS | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| ARTHRITIS BACTERIAL | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| BACTERIAL DISEASE CARRIER | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| BACTERIAL INFECTION | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| BILIARY SEPSIS | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| BRONCHITIS | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| CAMPYLOBACTER GASTROENTERITIS | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| CELLULITIS | | | |
| subjects affected / exposed | 4 / 406 (0.99%) | 16 / 406 (3.94%) | |
| occurrences causally related to treatment / all | 1 / 4 | 3 / 24 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| CELLULITIS STREPTOCOCCAL | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| CLOSTRIDIUM DIFFICILE INFECTION | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| COLONIC ABSCESS | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| CYSTITIS | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| DERMATITIS INFECTED | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| DEVICE RELATED INFECTION | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| DEVICE RELATED SEPSIS | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| DIVERTICULITIS | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 2 / 406 (0.49%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| ENDOCARDITIS | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| ERYSIPELAS | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 2 / 406 (0.49%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| FOLLICULITIS | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| FUNGAL INFECTION | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| GASTROENTERITIS | | | |
| subjects affected / exposed | 2 / 406 (0.49%) | 8 / 406 (1.97%) | |
| occurrences causally related to treatment / all | 0 / 2 | 1 / 8 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| GASTROENTERITIS ASTROVIRAL | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| GASTROENTERITIS NOROVIRUS | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 2 / 406 (0.49%) | 0 / 406 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| GASTROENTERITIS VIRAL | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 4 / 406 (0.99%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 4 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| GASTROINTESTINAL INFECTION | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| H1N1 INFLUENZA | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| HERPES ZOSTER | | | |
| subjects affected / exposed | 2 / 406 (0.49%) | 1 / 406 (0.25%) | |
| occurrences causally related to treatment / all | 1 / 2 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| INFECTION | | | |
| subjects affected / exposed | 2 / 406 (0.49%) | 4 / 406 (0.99%) | |
| occurrences causally related to treatment / all | 0 / 2 | 2 / 4 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| INFLUENZA | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 4 / 406 (0.99%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 4 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 1 | |
| KIDNEY INFECTION | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| LOCALISED INFECTION | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| LOWER RESPIRATORY TRACT INFECTION | | | |
| subjects affected / exposed | 8 / 406 (1.97%) | 14 / 406 (3.45%) | |
| occurrences causally related to treatment / all | 0 / 8 | 2 / 15 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| LUNG INFECTION | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 1 / 406 (0.25%) | |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| NEUTROPENIC SEPSIS | | | |
| subjects affected / exposed | 3 / 406 (0.74%) | 2 / 406 (0.49%) | |
| occurrences causally related to treatment / all | 3 / 3 | 1 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| ORCHITIS | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| OTITIS EXTERNA | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| PAROTITIS | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| PERINEAL INFECTION | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| PERIORBITAL CELLULITIS | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 406 (0.00%) | 2 / 406 (0.49%) | |
| occurrences causally related to treatment / all | 0 / 0 | 1 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| PNEUMOCYSTIS JIROVECII PNEUMONIA | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| PNEUMONIA | | | |
| subjects affected / exposed | 8 / 406 (1.97%) | 15 / 406 (3.69%) | |
| occurrences causally related to treatment / all | 0 / 8 | 1 / 15 | |
| deaths causally related to treatment / all | 0 / 3 | 0 / 1 | |
| PNEUMONIA PNEUMOCOCCAL | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| POST PROCEDURAL CELLULITIS | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| POSTOPERATIVE WOUND INFECTION | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| PYELONEPHRITIS ACUTE | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| RESPIRATORY SYNCYTIAL VIRUS INFECTION | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| RESPIRATORY TRACT INFECTION VIRAL | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| SCARLET FEVER | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| SEPSIS | | | |
| subjects affected / exposed | 5 / 406 (1.23%) | 3 / 406 (0.74%) | |
| occurrences causally related to treatment / all | 1 / 5 | 1 / 5 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| STITCH ABSCESS | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| STREPTOCOCCAL INFECTION | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| SUBCUTANEOUS ABSCESS | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| TUBERCULOSIS | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 1 / 406 (0.25%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| URINARY TRACT INFECTION | | | |
| subjects affected / exposed | 2 / 406 (0.49%) | 5 / 406 (1.23%) | |
| occurrences causally related to treatment / all | 0 / 2 | 1 / 5 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| UROSEPSIS | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 406 (0.00%) | 2 / 406 (0.49%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| VIRAL INFECTION | | | |
| subjects affected / exposed | 3 / 406 (0.74%) | 2 / 406 (0.49%) | |
| occurrences causally related to treatment / all | 0 / 3 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| VIRAL SEPSIS | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| VIRAL TONSILLITIS | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| WOUND INFECTION | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 2 / 406 (0.49%) | |
| occurrences causally related to treatment / all | 0 / 2 | 0 / 2 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Metabolism and nutrition disorders | | | |
| DEHYDRATION | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 3 / 406 (0.74%) | |
| occurrences causally related to treatment / all | 0 / 0 | 1 / 3 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| FLUID RETENTION | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| GOUT | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| HYPERGLYCAEMIA | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 406 (0.00%) | 2 / 406 (0.49%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 3 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| HYPERKALAEMIA | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 1 / 406 (0.25%) | |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| HYPERNATRAEMIA | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| HYPOGLYCAEMIA | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| HYPOKALAEMIA | | | |
| subjects affected / exposed | 2 / 406 (0.49%) | 0 / 406 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 3 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| HYPONATRAEMIA | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 1 / 406 (0.25%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |

Frequency threshold for reporting non-serious adverse events: 1 %

| **Non-serious adverse events** | Imatinib 400mg daily | Dasatinib 100mg daily | |
|---|---|---|---|
| Total subjects affected by non-serious adverse events | | | |
| subjects affected / exposed | 394 / 406 (97.04%) | 392 / 406 (96.55%) | |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | | | |
| ADRENAL ADENOMA | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences (all) | 0 | 1 | |
| B-CELL LYMPHOMA | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences (all) | 0 | 1 | |
| BASAL CELL CARCINOMA | | | |
| subjects affected / exposed | 4 / 406 (0.99%) | 1 / 406 (0.25%) | |
| occurrences (all) | 8 | 1 | |
| BENIGN BREAST NEOPLASM | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences (all) | 0 | 1 | |
| BENIGN NEOPLASM | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| FIBROADENOMA OF BREAST | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences (all) | 0 | 1 | |
| LIPOMA | | | |
| subjects affected / exposed | 2 / 406 (0.49%) | 1 / 406 (0.25%) | |
| occurrences (all) | 2 | 2 | |
| MELANOCYTIC NAEVUS | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences (all) | 0 | 1 | |
| PROSTATE CANCER | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| SARCOMA | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences (all) | 0 | 1 | |
| SCHWANNOMA | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences (all) | 0 | 1 | |
| SKIN PAPILLOMA | | | |
| subjects affected / exposed | 3 / 406 (0.74%) | 1 / 406 (0.25%) | |
| occurrences (all) | 4 | 1 | |
| UTERINE LEIOMYOMA | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Vascular disorders | | | |

| | | | | |
|---|---|---|---|---|
| ANGIODYSPLASIA | | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 2 / 406 (0.49%) | | |
| occurrences (all) | 0 | 2 | | |
| FLUSHING | | | | |
| subjects affected / exposed | 3 / 406 (0.74%) | 9 / 406 (2.22%) | | |
| occurrences (all) | 3 | 9 | | |
| HAEMATOMA | | | | |
| subjects affected / exposed | 2 / 406 (0.49%) | 2 / 406 (0.49%) | | |
| occurrences (all) | 2 | 3 | | |
| HOT FLUSH | | | | |
| subjects affected / exposed | 7 / 406 (1.72%) | 14 / 406 (3.45%) | | |
| occurrences (all) | 7 | 14 | | |
| HYPERTENSION | | | | |
| subjects affected / exposed | 5 / 406 (1.23%) | 12 / 406 (2.96%) | | |
| occurrences (all) | 5 | 13 | | |
| HYPOTENSION | | | | |
| subjects affected / exposed | 4 / 406 (0.99%) | 1 / 406 (0.25%) | | |
| occurrences (all) | 4 | 1 | | |
| LYMPHOEDEMA | | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 1 / 406 (0.25%) | | |
| occurrences (all) | 1 | 1 | | |
| ORTHOSTATIC HYPOTENSION | | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 1 / 406 (0.25%) | | |
| occurrences (all) | 1 | 1 | | |
| PERIPHERAL COLDNESS | | | | |
| subjects affected / exposed | 3 / 406 (0.74%) | 6 / 406 (1.48%) | | |
| occurrences (all) | 3 | 6 | | |
| PERIPHERAL ISCHAEMIA | | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | | |
| occurrences (all) | 1 | 0 | | |
| PHLEBITIS | | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | | |
| occurrences (all) | 0 | 1 | | |
| RAYNAUD'S PHENOMENON | | | | |
| subjects affected / exposed | 2 / 406 (0.49%) | 3 / 406 (0.74%) | | |
| occurrences (all) | 2 | 3 | | |

| | | | |
|---|---|---|---|
| THROMBOPHLEBITIS | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 3 / 406 (0.74%) | |
| occurrences (all) | 1 | 3 | |
| THROMBOSIS | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences (all) | 0 | 2 | |
| VARICOSE VEIN | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 1 / 406 (0.25%) | |
| occurrences (all) | 1 | 1 | |
| Surgical and medical procedures | | | |
| ABSCESS DRAINAGE | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| ANOPLASTY | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| CANCER SURGERY | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| CATARACT OPERATION | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| CIRCUMCISION | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| FINGER REPAIR OPERATION | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| INGUINAL HERNIA REPAIR | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences (all) | 0 | 1 | |
| KNEE ARTHROPLASTY | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences (all) | 0 | 1 | |
| LIPOMA EXCISION | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences (all) | 0 | 1 | |
| MANIPULATION | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences (all) | 0 | 1 | |
| MOLE EXCISION | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences (all) | 0 | 1 | |
| NASAL SEPTAL OPERATION | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences (all) | 0 | 1 | |
| SALPINGO-OOPHORECTOMY BILATERAL | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences (all) | 0 | 1 | |
| SKIN NEOPLASM EXCISION | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences (all) | 0 | 1 | |
| TONSILLECTOMY | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| TOOTH EXTRACTION | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 2 / 406 (0.49%) | |
| occurrences (all) | 0 | 2 | |
| UMBILICAL HERNIA REPAIR | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences (all) | 0 | 1 | |
| UVULECTOMY | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| General disorders and administration site conditions | | | |
| ADVERSE DRUG REACTION | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences (all) | 0 | 1 | |
| ASTHENIA | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 2 / 406 (0.49%) | 2 / 406 (0.49%) | |
| occurrences (all) | 2 | 2 | |
| AXILLARY PAIN | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences (all) | 0 | 1 | |
| CHEST DISCOMFORT | | | |
| subjects affected / exposed | 5 / 406 (1.23%) | 7 / 406 (1.72%) | |
| occurrences (all) | 5 | 7 | |
| CHEST PAIN | | | |
| subjects affected / exposed | 12 / 406 (2.96%) | 24 / 406 (5.91%) | |
| occurrences (all) | 13 | 27 | |
| CHILLS | | | |
| subjects affected / exposed | 5 / 406 (1.23%) | 8 / 406 (1.97%) | |
| occurrences (all) | 5 | 8 | |
| CYST | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| DISCOMFORT | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences (all) | 0 | 1 | |
| FACE OEDEMA | | | |
| subjects affected / exposed | 7 / 406 (1.72%) | 5 / 406 (1.23%) | |
| occurrences (all) | 7 | 5 | |
| FATIGUE | | | |
| subjects affected / exposed | 123 / 406 (30.30%) | 147 / 406 (36.21%) | |
| occurrences (all) | 146 | 196 | |
| FEELING ABNORMAL | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 1 / 406 (0.25%) | |
| occurrences (all) | 1 | 1 | |
| FEELING COLD | | | |
| subjects affected / exposed | 4 / 406 (0.99%) | 8 / 406 (1.97%) | |
| occurrences (all) | 4 | 8 | |
| FEELING HOT | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 2 / 406 (0.49%) | |
| occurrences (all) | 0 | 2 | |
| GENERALISED OEDEMA | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| GRANULOMA | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| HERNIA | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 1 / 406 (0.25%) | |
| occurrences (all) | 1 | 1 | |
| HERNIA PAIN | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences (all) | 0 | 1 | |
| HUNGER | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences (all) | 0 | 1 | |
| INFLUENZA LIKE ILLNESS | | | |
| subjects affected / exposed | 14 / 406 (3.45%) | 17 / 406 (4.19%) | |
| occurrences (all) | 20 | 18 | |
| LOCAL SWELLING | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 6 / 406 (1.48%) | |
| occurrences (all) | 1 | 8 | |
| LOCALISED OEDEMA | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences (all) | 0 | 1 | |
| MALAISE | | | |
| subjects affected / exposed | 6 / 406 (1.48%) | 10 / 406 (2.46%) | |
| occurrences (all) | 6 | 11 | |
| MASS | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 6 / 406 (1.48%) | |
| occurrences (all) | 1 | 7 | |
| MUCOSAL INFLAMMATION | | | |
| subjects affected / exposed | 3 / 406 (0.74%) | 3 / 406 (0.74%) | |
| occurrences (all) | 3 | 3 | |
| NODULE | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences (all) | 0 | 1 | |
| NON-CARDIAC CHEST PAIN | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 406 (0.00%) | 2 / 406 (0.49%) | |
| occurrences (all) | 0 | 2 | |
| OEDEMA | | | |
| subjects affected / exposed | 8 / 406 (1.97%) | 5 / 406 (1.23%) | |
| occurrences (all) | 8 | 5 | |
| OEDEMA PERIPHERAL | | | |
| subjects affected / exposed | 31 / 406 (7.64%) | 17 / 406 (4.19%) | |
| occurrences (all) | 40 | 22 | |
| PAIN | | | |
| subjects affected / exposed | 18 / 406 (4.43%) | 16 / 406 (3.94%) | |
| occurrences (all) | 20 | 16 | |
| PERIPHERAL SWELLING | | | |
| subjects affected / exposed | 14 / 406 (3.45%) | 6 / 406 (1.48%) | |
| occurrences (all) | 16 | 7 | |
| POLYP | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| PYREXIA | | | |
| subjects affected / exposed | 9 / 406 (2.22%) | 18 / 406 (4.43%) | |
| occurrences (all) | 10 | 22 | |
| SENSATION OF BLOOD FLOW | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences (all) | 0 | 1 | |
| SUPRAPUBIC PAIN | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences (all) | 0 | 1 | |
| SWELLING | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 2 / 406 (0.49%) | |
| occurrences (all) | 0 | 2 | |
| TEMPERATURE INTOLERANCE | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 1 / 406 (0.25%) | |
| occurrences (all) | 1 | 2 | |
| TENDERNESS | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| THIRST | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 3 / 406 (0.74%) | 1 / 406 (0.25%) | |
| occurrences (all) | 3 | 1 | |
| ULCER | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences (all) | 0 | 1 | |
| Immune system disorders | | | |
| DRUG HYPERSENSITIVITY | | | |
| subjects affected / exposed | 2 / 406 (0.49%) | 6 / 406 (1.48%) | |
| occurrences (all) | 2 | 6 | |
| HYPERSENSITIVITY | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 2 / 406 (0.49%) | |
| occurrences (all) | 1 | 2 | |
| HYPOGAMMAGLOBULINAEMIA | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| SEASONAL ALLERGY | | | |
| subjects affected / exposed | 2 / 406 (0.49%) | 10 / 406 (2.46%) | |
| occurrences (all) | 2 | 10 | |
| Social circumstances | | | |
| MENOPAUSE | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences (all) | 0 | 1 | |
| Reproductive system and breast disorders | | | |
| BENIGN PROSTATIC HYPERPLASIA | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences (all) | 0 | 1 | |
| BREAST DISCHARGE | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences (all) | 0 | 1 | |
| BREAST MASS | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 1 / 406 (0.25%) | |
| occurrences (all) | 1 | 2 | |
| BREAST OEDEMA | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences (all) | 0 | 1 | |
| BREAST PAIN | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 1 / 406 (0.25%) | 1 / 406 (0.25%) | |
| occurrences (all) | 1 | 1 | |
| BREAST SWELLING | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences (all) | 0 | 1 | |
| BREAST TENDERNESS | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 2 / 406 (0.49%) | |
| occurrences (all) | 0 | 2 | |
| CERVICAL DYSPLASIA | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences (all) | 0 | 1 | |
| DYSMENORRHOEA | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | |
| occurrences (all) | 2 | 0 | |
| ENDOMETRIOSIS | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| ERECTILE DYSFUNCTION | | | |
| subjects affected / exposed | 5 / 406 (1.23%) | 2 / 406 (0.49%) | |
| occurrences (all) | 6 | 2 | |
| GENITAL PAIN | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| GYNAECOMASTIA | | | |
| subjects affected / exposed | 2 / 406 (0.49%) | 5 / 406 (1.23%) | |
| occurrences (all) | 2 | 6 | |
| MENORRHAGIA | | | |
| subjects affected / exposed | 5 / 406 (1.23%) | 7 / 406 (1.72%) | |
| occurrences (all) | 6 | 8 | |
| MENSTRUATION IRREGULAR | | | |
| subjects affected / exposed | 4 / 406 (0.99%) | 3 / 406 (0.74%) | |
| occurrences (all) | 4 | 3 | |
| METRORRHAGIA | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| NIPPLE PAIN | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 406 (0.00%) | 2 / 406 (0.49%) | |
| occurrences (all) | 0 | 2 | |
| OEDEMA GENITAL | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences (all) | 0 | 1 | |
| OVARIAN CYST | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences (all) | 0 | 1 | |
| PELVIC PAIN | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 1 / 406 (0.25%) | |
| occurrences (all) | 1 | 1 | |
| PENILE PAIN | | | |
| subjects affected / exposed | 2 / 406 (0.49%) | 0 / 406 (0.00%) | |
| occurrences (all) | 2 | 0 | |
| PENILE SWELLING | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences (all) | 0 | 1 | |
| PERINEAL PAIN | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| POLYMENORRHOEA | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences (all) | 0 | 1 | |
| PRIAPISM | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| PROSTATITIS | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences (all) | 0 | 1 | |
| PROSTATOMEGALY | | | |
| subjects affected / exposed | 2 / 406 (0.49%) | 2 / 406 (0.49%) | |
| occurrences (all) | 2 | 2 | |
| SCROTAL OEDEMA | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences (all) | 0 | 1 | |
| TESTICULAR PAIN | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 1 / 406 (0.25%) | 5 / 406 (1.23%) | |
| occurrences (all) | 1 | 5 | |
| TESTICULAR SWELLING | | | |
| subjects affected / exposed | 2 / 406 (0.49%) | 2 / 406 (0.49%) | |
| occurrences (all) | 2 | 2 | |
| VAGINAL CYST | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| VAGINAL DISCHARGE | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 2 / 406 (0.49%) | |
| occurrences (all) | 0 | 2 | |
| VAGINAL HAEMORRHAGE | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 7 / 406 (1.72%) | |
| occurrences (all) | 0 | 8 | |
| Respiratory, thoracic and mediastinal disorders | | | |
| ASTHMA | | | |
| subjects affected / exposed | 2 / 406 (0.49%) | 3 / 406 (0.74%) | |
| occurrences (all) | 2 | 4 | |
| ATELECTASIS | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences (all) | 0 | 1 | |
| BRONCHOSPASM | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences (all) | 0 | 1 | |
| CATARRH | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| CHRONIC OBSTRUCTIVE PULMONARY DISEASE | | | |
| subjects affected / exposed | 2 / 406 (0.49%) | 3 / 406 (0.74%) | |
| occurrences (all) | 2 | 3 | |
| COUGH | | | |
| subjects affected / exposed | 30 / 406 (7.39%) | 60 / 406 (14.78%) | |
| occurrences (all) | 32 | 70 | |
| DIAPHRAGMALGIA | | | |

| | | | | |
|---|---|---|---|---|
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | | |
| occurrences (all) | 0 | 1 | | |
| DRY THROAT | | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 2 / 406 (0.49%) | | |
| occurrences (all) | 0 | 2 | | |
| DYSPHONIA | | | | |
| subjects affected / exposed | 3 / 406 (0.74%) | 4 / 406 (0.99%) | | |
| occurrences (all) | 3 | 4 | | |
| DYSPNOEA | | | | |
| subjects affected / exposed | 35 / 406 (8.62%) | 99 / 406 (24.38%) | | |
| occurrences (all) | 38 | 134 | | |
| DYSPNOEA AT REST | | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | | |
| occurrences (all) | 0 | 1 | | |
| DYSPNOEA EXERTIONAL | | | | |
| subjects affected / exposed | 12 / 406 (2.96%) | 22 / 406 (5.42%) | | |
| occurrences (all) | 12 | 25 | | |
| DYSPNOEA PAROXYSMAL NOCTURNAL | | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | | |
| occurrences (all) | 0 | 1 | | |
| EPISTAXIS | | | | |
| subjects affected / exposed | 10 / 406 (2.46%) | 8 / 406 (1.97%) | | |
| occurrences (all) | 13 | 8 | | |
| HAEMOPTYSIS | | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | | |
| occurrences (all) | 1 | 0 | | |
| HICCUPS | | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | | |
| occurrences (all) | 1 | 0 | | |
| HYPOXIA | | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | | |
| occurrences (all) | 0 | 1 | | |
| INTERSTITIAL LUNG DISEASE | | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | | |
| occurrences (all) | 1 | 0 | | |

| | | | |
|---|---|---|---|
| LARYNGEAL INFLAMMATION | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences (all) | 0 | 1 | |
| LARYNGEAL POLYP | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences (all) | 0 | 1 | |
| LUNG CONSOLIDATION | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences (all) | 0 | 1 | |
| NASAL CONGESTION | | | |
| subjects affected / exposed | 3 / 406 (0.74%) | 2 / 406 (0.49%) | |
| occurrences (all) | 5 | 2 | |
| OROPHARYNGEAL PAIN | | | |
| subjects affected / exposed | 18 / 406 (4.43%) | 28 / 406 (6.90%) | |
| occurrences (all) | 20 | 30 | |
| ORTHOPNOEA | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences (all) | 0 | 1 | |
| PHARYNGEAL LEUKOPLAKIA | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| PHARYNGEAL OEDEMA | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| PLEURAL EFFUSION | | | |
| subjects affected / exposed | 4 / 406 (0.99%) | 108 / 406 (26.60%) | |
| occurrences (all) | 4 | 193 | |
| PLEURISY | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| PLEURITIC PAIN | | | |
| subjects affected / exposed | 3 / 406 (0.74%) | 2 / 406 (0.49%) | |
| occurrences (all) | 3 | 2 | |
| PNEUMONITIS | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences (all) | 0 | 1 | |

| | | | |
|---|---|---|---|
| PRODUCTIVE COUGH | | | |
| subjects affected / exposed | 4 / 406 (0.99%) | 13 / 406 (3.20%) | |
| occurrences (all) | 5 | 13 | |
| PULMONARY CONGESTION | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 2 / 406 (0.49%) | |
| occurrences (all) | 0 | 2 | |
| PULMONARY EMBOLISM | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences (all) | 0 | 1 | |
| PULMONARY FIBROSIS | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| PULMONARY HAEMORRHAGE | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences (all) | 0 | 1 | |
| PULMONARY HYPERTENSION | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 2 / 406 (0.49%) | |
| occurrences (all) | 0 | 2 | |
| PULMONARY OEDEMA | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences (all) | 0 | 1 | |
| PULMONARY SARCOIDOSIS | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences (all) | 0 | 1 | |
| RHINITIS ALLERGIC | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 1 / 406 (0.25%) | |
| occurrences (all) | 1 | 1 | |
| RHINORRHOEA | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 2 / 406 (0.49%) | |
| occurrences (all) | 0 | 2 | |
| SINUS CONGESTION | | | |
| subjects affected / exposed | 2 / 406 (0.49%) | 0 / 406 (0.00%) | |
| occurrences (all) | 2 | 0 | |
| SINUS PAIN | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences (all) | 0 | 1 | |

| | | | |
|---|---|---|---|
| SLEEP APNOEA SYNDROME | | | |
| subjects affected / exposed | 2 / 406 (0.49%) | 1 / 406 (0.25%) | |
| occurrences (all) | 2 | 1 | |
| THROAT IRRITATION | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences (all) | 0 | 1 | |
| VOCAL CORD CYST | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences (all) | 0 | 1 | |
| WHEEZING | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 7 / 406 (1.72%) | |
| occurrences (all) | 1 | 7 | |
| Psychiatric disorders | | | |
| ABNORMAL DREAMS | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences (all) | 0 | 1 | |
| AFFECT LABILITY | | | |
| subjects affected / exposed | 2 / 406 (0.49%) | 0 / 406 (0.00%) | |
| occurrences (all) | 2 | 0 | |
| AFFECTIVE DISORDER | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences (all) | 0 | 1 | |
| AGGRESSION | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences (all) | 0 | 1 | |
| AGITATION | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences (all) | 0 | 1 | |
| ANXIETY | | | |
| subjects affected / exposed | 7 / 406 (1.72%) | 13 / 406 (3.20%) | |
| occurrences (all) | 7 | 17 | |
| CONFUSIONAL STATE | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 2 / 406 (0.49%) | |
| occurrences (all) | 1 | 2 | |
| DEPRESSED MOOD | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 7 / 406 (1.72%) | 18 / 406 (4.43%) | |
| occurrences (all) | 7 | 19 | |
| DEPRESSION | | | |
| subjects affected / exposed | 16 / 406 (3.94%) | 30 / 406 (7.39%) | |
| occurrences (all) | 16 | 30 | |
| DEPRESSIVE SYMPTOM | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences (all) | 0 | 1 | |
| EATING DISORDER | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| HALLUCINATION | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | |
| occurrences (all) | 2 | 0 | |
| INSOMNIA | | | |
| subjects affected / exposed | 25 / 406 (6.16%) | 23 / 406 (5.67%) | |
| occurrences (all) | 26 | 25 | |
| IRRITABILITY | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences (all) | 0 | 1 | |
| LIBIDO DECREASED | | | |
| subjects affected / exposed | 2 / 406 (0.49%) | 1 / 406 (0.25%) | |
| occurrences (all) | 2 | 1 | |
| LOSS OF LIBIDO | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 1 / 406 (0.25%) | |
| occurrences (all) | 1 | 1 | |
| MENTAL DISORDER | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences (all) | 0 | 1 | |
| MOOD ALTERED | | | |
| subjects affected / exposed | 4 / 406 (0.99%) | 7 / 406 (1.72%) | |
| occurrences (all) | 4 | 7 | |
| MOOD SWINGS | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| PANIC ATTACK | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 406 (0.00%) | 4 / 406 (0.99%) | |
| occurrences (all) | 0 | 4 | |
| PERSONALITY DISORDER | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences (all) | 0 | 1 | |
| PSYCHIATRIC SYMPTOM | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 1 / 406 (0.25%) | |
| occurrences (all) | 1 | 1 | |
| SCHIZOPHRENIA | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences (all) | 0 | 1 | |
| SLEEP DISORDER | | | |
| subjects affected / exposed | 6 / 406 (1.48%) | 3 / 406 (0.74%) | |
| occurrences (all) | 6 | 3 | |
| STRESS | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 2 / 406 (0.49%) | |
| occurrences (all) | 1 | 2 | |
| SUICIDE ATTEMPT | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences (all) | 0 | 1 | |
| Product issues | | | |
| DEVICE DAMAGE | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences (all) | 0 | 1 | |
| Hepatobiliary disorders | | | |
| CHOLELITHIASIS | | | |
| subjects affected / exposed | 2 / 406 (0.49%) | 1 / 406 (0.25%) | |
| occurrences (all) | 2 | 1 | |
| GALLBLADDER PAIN | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences (all) | 0 | 1 | |
| HEPATIC CIRRHOSIS | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences (all) | 0 | 1 | |
| HEPATIC FUNCTION ABNORMAL | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences (all) | 0 | 1 | |
| HEPATIC STEATOSIS | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences (all) | 0 | 1 | |
| Investigations | | | |
| ALANINE AMINOTRANSFERASE INCREASED | | | |
| subjects affected / exposed | 7 / 406 (1.72%) | 5 / 406 (1.23%) | |
| occurrences (all) | 8 | 10 | |
| ASPARTATE AMINOTRANSFERASE INCREASED | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 1 / 406 (0.25%) | |
| occurrences (all) | 1 | 5 | |
| BIOPSY PROSTATE | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences (all) | 0 | 1 | |
| BLOOD ALKALINE PHOSPHATASE INCREASED | | | |
| subjects affected / exposed | 5 / 406 (1.23%) | 0 / 406 (0.00%) | |
| occurrences (all) | 5 | 0 | |
| BLOOD BILIRUBIN INCREASED | | | |
| subjects affected / exposed | 2 / 406 (0.49%) | 1 / 406 (0.25%) | |
| occurrences (all) | 2 | 2 | |
| BLOOD CALCIUM DECREASED | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| BLOOD CHOLESTEROL INCREASED | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 4 / 406 (0.99%) | |
| occurrences (all) | 1 | 4 | |
| BLOOD COUNT ABNORMAL | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences (all) | 0 | 1 | |
| BLOOD CREATINE PHOSPHOKINASE INCREASED | | | |
| subjects affected / exposed | 2 / 406 (0.49%) | 1 / 406 (0.25%) | |
| occurrences (all) | 2 | 1 | |
| BLOOD CREATININE INCREASED | | | |

| | | | | |
|---|---|---|---|---|
| subjects affected / exposed | 3 / 406 (0.74%) | 3 / 406 (0.74%) | | |
| occurrences (all) | 3 | 3 | | |
| BLOOD FOLATE DECREASED | | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | | |
| occurrences (all) | 1 | 0 | | |
| BLOOD GLUCOSE INCREASED | | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | | |
| occurrences (all) | 1 | 0 | | |
| BLOOD IRON DECREASED | | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | | |
| occurrences (all) | 0 | 1 | | |
| BLOOD LACTATE DEHYDROGENASE INCREASED | | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | | |
| occurrences (all) | 0 | 1 | | |
| BLOOD PHOSPHORUS DECREASED | | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | | |
| occurrences (all) | 1 | 0 | | |
| BLOOD POTASSIUM DECREASED | | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | | |
| occurrences (all) | 1 | 0 | | |
| BLOOD PRESSURE INCREASED | | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | | |
| occurrences (all) | 1 | 0 | | |
| BLOOD THYROID STIMULATING HORMONE INCREASED | | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | | |
| occurrences (all) | 1 | 0 | | |
| BORRELIA TEST | | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | | |
| occurrences (all) | 1 | 0 | | |
| CARDIAC MURMUR | | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 3 / 406 (0.74%) | | |
| occurrences (all) | 0 | 3 | | |
| CLOSTRIDIUM TEST POSITIVE | | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences (all) | 0 | 1 | |
| COLONOSCOPY | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences (all) | 0 | 1 | |
| ECHOCARDIOGRAM ABNORMAL | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences (all) | 0 | 1 | |
| ELECTROCARDIOGRAM PR SHORTENED | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| ENDOSCOPY UPPER GASTROINTESTINAL TRACT | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 1 / 406 (0.25%) | |
| occurrences (all) | 1 | 1 | |
| GAMMA-GLUTAMYLTRANSFERASE | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences (all) | 0 | 1 | |
| GAMMA-GLUTAMYLTRANSFERASE INCREASED | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 1 / 406 (0.25%) | |
| occurrences (all) | 1 | 1 | |
| HAEMOGLOBIN DECREASED | | | |
| subjects affected / exposed | 3 / 406 (0.74%) | 8 / 406 (1.97%) | |
| occurrences (all) | 3 | 9 | |
| INTRAOCULAR PRESSURE INCREASED | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| LIVER FUNCTION TEST ABNORMAL | | | |
| subjects affected / exposed | 2 / 406 (0.49%) | 1 / 406 (0.25%) | |
| occurrences (all) | 2 | 1 | |
| MENSTRUATION NORMAL | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences (all) | 0 | 1 | |
| NEUTROPHIL COUNT | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 1 / 406 (0.25%) | 2 / 406 (0.49%) | |
| occurrences (all) | 2 | 2 | |
| NEUTROPHIL COUNT DECREASED | | | |
| subjects affected / exposed | 4 / 406 (0.99%) | 7 / 406 (1.72%) | |
| occurrences (all) | 5 | 10 | |
| PLATELET COUNT DECREASED | | | |
| subjects affected / exposed | 7 / 406 (1.72%) | 11 / 406 (2.71%) | |
| occurrences (all) | 9 | 20 | |
| PROSTATIC SPECIFIC ANTIGEN INCREASED | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| PROTEIN URINE PRESENT | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences (all) | 0 | 1 | |
| SERUM FERRITIN DECREASED | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 7 / 406 (1.72%) | |
| occurrences (all) | 0 | 8 | |
| STREPTOCOCCUS TEST POSITIVE | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences (all) | 0 | 1 | |
| THYROID FUNCTION TEST ABNORMAL | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences (all) | 0 | 1 | |
| VITAMIN B12 DECREASED | | | |
| subjects affected / exposed | 2 / 406 (0.49%) | 0 / 406 (0.00%) | |
| occurrences (all) | 2 | 0 | |
| VITAMIN D DECREASED | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| WEIGHT DECREASED | | | |
| subjects affected / exposed | 7 / 406 (1.72%) | 15 / 406 (3.69%) | |
| occurrences (all) | 8 | 15 | |
| WEIGHT INCREASED | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 15 / 406 (3.69%) | 7 / 406 (1.72%) | |
| occurrences (all) | 15 | 12 | |
| WHITE BLOOD CELL COUNT | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences (all) | 0 | 2 | |
| WHITE BLOOD CELL COUNT DECREASED | | | |
| subjects affected / exposed | 2 / 406 (0.49%) | 4 / 406 (0.99%) | |
| occurrences (all) | 2 | 4 | |
| WHITE BLOOD CELL COUNT INCREASED | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences (all) | 0 | 1 | |
| Injury, poisoning and procedural complications | | | |
| ACCIDENTAL OVERDOSE | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| ANKLE FRACTURE | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences (all) | 0 | 1 | |
| ARTHROPOD BITE | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 3 / 406 (0.74%) | |
| occurrences (all) | 0 | 3 | |
| AVULSION FRACTURE | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences (all) | 0 | 1 | |
| CHEST INJURY | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| CLAVICLE FRACTURE | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| CONTUSION | | | |
| subjects affected / exposed | 8 / 406 (1.97%) | 9 / 406 (2.22%) | |
| occurrences (all) | 8 | 9 | |
| DENTAL RESTORATION FAILURE | | | |

| | | | | |
|---|---|---|---|---|
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | | |
| occurrences (all) | 1 | 0 | | |
| EPICONDYLITIS | | | | |
| subjects affected / exposed | 2 / 406 (0.49%) | 1 / 406 (0.25%) | | |
| occurrences (all) | 2 | 1 | | |
| EYE CONTUSION | | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | | |
| occurrences (all) | 1 | 0 | | |
| FALL | | | | |
| subjects affected / exposed | 8 / 406 (1.97%) | 11 / 406 (2.71%) | | |
| occurrences (all) | 9 | 14 | | |
| FOOT FRACTURE | | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 2 / 406 (0.49%) | | |
| occurrences (all) | 1 | 2 | | |
| FRACTURE | | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | | |
| occurrences (all) | 1 | 0 | | |
| GASTROINTESTINAL STOMA COMPLICATION | | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | | |
| occurrences (all) | 1 | 0 | | |
| HEAD INJURY | | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | | |
| occurrences (all) | 0 | 1 | | |
| INJURY | | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | | |
| occurrences (all) | 0 | 1 | | |
| JOINT DISLOCATION | | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | | |
| occurrences (all) | 0 | 1 | | |
| JOINT INJURY | | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 2 / 406 (0.49%) | | |
| occurrences (all) | 0 | 2 | | |
| LACERATION | | | | |
| subjects affected / exposed | 6 / 406 (1.48%) | 0 / 406 (0.00%) | | |
| occurrences (all) | 6 | 0 | | |

| | | | |
|---|---|---|---|
| LIGAMENT RUPTURE | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 1 / 406 (0.25%) | |
| occurrences (all) | 1 | 1 | |
| LIGAMENT SPRAIN | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 1 / 406 (0.25%) | |
| occurrences (all) | 1 | 1 | |
| LIMB INJURY | | | |
| subjects affected / exposed | 2 / 406 (0.49%) | 3 / 406 (0.74%) | |
| occurrences (all) | 2 | 3 | |
| MEDICATION ERROR | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| MENISCUS INJURY | | | |
| subjects affected / exposed | 2 / 406 (0.49%) | 1 / 406 (0.25%) | |
| occurrences (all) | 2 | 1 | |
| MUSCLE STRAIN | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 1 / 406 (0.25%) | |
| occurrences (all) | 1 | 2 | |
| NECK INJURY | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| POST PROCEDURAL DISCOMFORT | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| POST PROCEDURAL HAEMORRHAGE | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences (all) | 0 | 1 | |
| POST-TRAUMATIC NECK SYNDROME | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| PROCEDURAL DIZZINESS | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences (all) | 0 | 1 | |
| PROCEDURAL PAIN | | | |
| subjects affected / exposed | 2 / 406 (0.49%) | 1 / 406 (0.25%) | |
| occurrences (all) | 2 | 1 | |

| | | | |
|---|---|---|---|
| RIB FRACTURE | | | |
| subjects affected / exposed | 3 / 406 (0.74%) | 1 / 406 (0.25%) | |
| occurrences (all) | 3 | 1 | |
| SOFT TISSUE INJURY | | | |
| subjects affected / exposed | 2 / 406 (0.49%) | 1 / 406 (0.25%) | |
| occurrences (all) | 2 | 1 | |
| SUNBURN | | | |
| subjects affected / exposed | 2 / 406 (0.49%) | 0 / 406 (0.00%) | |
| occurrences (all) | 2 | 0 | |
| TENDON RUPTURE | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 2 / 406 (0.49%) | |
| occurrences (all) | 1 | 2 | |
| THERMAL BURN | | | |
| subjects affected / exposed | 2 / 406 (0.49%) | 0 / 406 (0.00%) | |
| occurrences (all) | 3 | 0 | |
| UPPER LIMB FRACTURE | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | |
| occurrences (all) | 2 | 0 | |
| VACCINATION COMPLICATION | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 2 / 406 (0.49%) | |
| occurrences (all) | 0 | 2 | |
| WRIST FRACTURE | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | |
| occurrences (all) | 2 | 0 | |
| Congenital, familial and genetic disorders | | | |
| GILBERT'S SYNDROME | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences (all) | 0 | 1 | |
| HYDROCELE | | | |
| subjects affected / exposed | 3 / 406 (0.74%) | 2 / 406 (0.49%) | |
| occurrences (all) | 3 | 2 | |
| PHIMOSIS | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Cardiac disorders | | | |

| | | | |
|---|---|---|---|
| ANGINA PECTORIS | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 4 / 406 (0.99%) | |
| occurrences (all) | 0 | 4 | |
| ARRHYTHMIA | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences (all) | 0 | 1 | |
| ATRIAL FIBRILLATION | | | |
| subjects affected / exposed | 3 / 406 (0.74%) | 6 / 406 (1.48%) | |
| occurrences (all) | 3 | 7 | |
| BRADYCARDIA | | | |
| subjects affected / exposed | 2 / 406 (0.49%) | 2 / 406 (0.49%) | |
| occurrences (all) | 2 | 2 | |
| BUNDLE BRANCH BLOCK RIGHT | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| CARDIAC FAILURE CHRONIC | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences (all) | 0 | 1 | |
| CARDIAC VALVE DISEASE | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| CARDIOMEGALY | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| CARDIOMYOPATHY | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| CARDIOTOXICITY | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences (all) | 0 | 1 | |
| CONDUCTION DISORDER | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences (all) | 0 | 1 | |
| DIASTOLIC DYSFUNCTION | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 1 / 406 (0.25%) | |
| occurrences (all) | 1 | 1 | |

| | | | |
|---|---|---|---|
| LEFT VENTRICULAR DYSFUNCTION | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences (all) | 0 | 1 | |
| LEFT VENTRICULAR FAILURE | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences (all) | 0 | 1 | |
| LEFT VENTRICULAR HYPERTROPHY | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| MITRAL VALVE INCOMPETENCE | | | |
| subjects affected / exposed | 2 / 406 (0.49%) | 0 / 406 (0.00%) | |
| occurrences (all) | 2 | 0 | |
| MYOCARDIAL ISCHAEMIA | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 2 / 406 (0.49%) | |
| occurrences (all) | 0 | 2 | |
| PALPITATIONS | | | |
| subjects affected / exposed | 9 / 406 (2.22%) | 17 / 406 (4.19%) | |
| occurrences (all) | 11 | 19 | |
| PERICARDIAL EFFUSION | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 7 / 406 (1.72%) | |
| occurrences (all) | 1 | 7 | |
| PERICARDITIS | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 1 / 406 (0.25%) | |
| occurrences (all) | 1 | 2 | |
| SUPRAVENTRICULAR EXTRASYSTOLES | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| TACHYCARDIA | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 2 / 406 (0.49%) | |
| occurrences (all) | 0 | 2 | |
| Nervous system disorders | | | |
| AGEUSIA | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 1 / 406 (0.25%) | |
| occurrences (all) | 1 | 1 | |
| AMNESIA | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 2 / 406 (0.49%) | 5 / 406 (1.23%) | |
| occurrences (all) | 2 | 5 | |
| BALANCE DISORDER | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| BURNING SENSATION | | | |
| subjects affected / exposed | 2 / 406 (0.49%) | 1 / 406 (0.25%) | |
| occurrences (all) | 2 | 1 | |
| CAROTID ARTERY CALCIFICATION | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| CARPAL TUNNEL SYNDROME | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 5 / 406 (1.23%) | |
| occurrences (all) | 0 | 6 | |
| CEREBELLAR INFARCTION | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences (all) | 0 | 1 | |
| CLUSTER HEADACHE | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences (all) | 0 | 1 | |
| COGNITIVE DISORDER | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 1 / 406 (0.25%) | |
| occurrences (all) | 1 | 1 | |
| DEMENTIA | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences (all) | 0 | 2 | |
| DISTURBANCE IN ATTENTION | | | |
| subjects affected / exposed | 4 / 406 (0.99%) | 2 / 406 (0.49%) | |
| occurrences (all) | 4 | 2 | |
| DIZZINESS | | | |
| subjects affected / exposed | 29 / 406 (7.14%) | 36 / 406 (8.87%) | |
| occurrences (all) | 31 | 45 | |
| DIZZINESS POSTURAL | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| DYSGEUSIA | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 13 / 406 (3.20%) | 9 / 406 (2.22%) | |
| occurrences (all) | 13 | 9 | |
| DYSKINESIA | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 1 / 406 (0.25%) | |
| occurrences (all) | 1 | 1 | |
| DYSTONIA | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| EXERTIONAL HEADACHE | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences (all) | 0 | 1 | |
| FACIAL PARALYSIS | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences (all) | 0 | 1 | |
| HEADACHE | | | |
| subjects affected / exposed | 61 / 406 (15.02%) | 110 / 406 (27.09%) | |
| occurrences (all) | 75 | 140 | |
| HYPERAESTHESIA | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 2 / 406 (0.49%) | |
| occurrences (all) | 0 | 2 | |
| HYPOAESTHESIA | | | |
| subjects affected / exposed | 11 / 406 (2.71%) | 8 / 406 (1.97%) | |
| occurrences (all) | 12 | 9 | |
| LETHARGY | | | |
| subjects affected / exposed | 39 / 406 (9.61%) | 34 / 406 (8.37%) | |
| occurrences (all) | 42 | 37 | |
| LOSS OF CONSCIOUSNESS | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 1 / 406 (0.25%) | |
| occurrences (all) | 1 | 1 | |
| MEMORY IMPAIRMENT | | | |
| subjects affected / exposed | 3 / 406 (0.74%) | 8 / 406 (1.97%) | |
| occurrences (all) | 4 | 8 | |
| MENTAL IMPAIRMENT | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 1 / 406 (0.25%) | |
| occurrences (all) | 1 | 1 | |
| MIGRAINE | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 6 / 406 (1.48%) | 3 / 406 (0.74%) | |
| occurrences (all) | 6 | 3 | |
| NERVE COMPRESSION | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 2 / 406 (0.49%) | |
| occurrences (all) | 1 | 2 | |
| NEURALGIA | | | |
| subjects affected / exposed | 5 / 406 (1.23%) | 3 / 406 (0.74%) | |
| occurrences (all) | 5 | 3 | |
| NEUROLOGICAL SYMPTOM | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| NEUROPATHY PERIPHERAL | | | |
| subjects affected / exposed | 8 / 406 (1.97%) | 5 / 406 (1.23%) | |
| occurrences (all) | 9 | 5 | |
| PARAESTHESIA | | | |
| subjects affected / exposed | 12 / 406 (2.96%) | 15 / 406 (3.69%) | |
| occurrences (all) | 14 | 16 | |
| PERIPHERAL MOTOR NEUROPATHY | | | |
| subjects affected / exposed | 2 / 406 (0.49%) | 0 / 406 (0.00%) | |
| occurrences (all) | 2 | 0 | |
| PERIPHERAL SENSORY NEUROPATHY | | | |
| subjects affected / exposed | 3 / 406 (0.74%) | 8 / 406 (1.97%) | |
| occurrences (all) | 3 | 8 | |
| POOR QUALITY SLEEP | | | |
| subjects affected / exposed | 2 / 406 (0.49%) | 0 / 406 (0.00%) | |
| occurrences (all) | 2 | 0 | |
| POST HERPETIC NEURALGIA | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| PRESYNCOPE | | | |
| subjects affected / exposed | 3 / 406 (0.74%) | 0 / 406 (0.00%) | |
| occurrences (all) | 3 | 0 | |
| RESTLESS LEGS SYNDROME | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 2 / 406 (0.49%) | |
| occurrences (all) | 1 | 2 | |
| SCIATICA | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 4 / 406 (0.99%) | 7 / 406 (1.72%) | |
| occurrences (all) | 5 | 8 | |
| SEIZURE | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| SENSORY DISTURBANCE | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 2 / 406 (0.49%) | |
| occurrences (all) | 0 | 2 | |
| SOMNOLENCE | | | |
| subjects affected / exposed | 2 / 406 (0.49%) | 1 / 406 (0.25%) | |
| occurrences (all) | 3 | 1 | |
| SPEECH DISORDER | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| SYNCOPE | | | |
| subjects affected / exposed | 5 / 406 (1.23%) | 4 / 406 (0.99%) | |
| occurrences (all) | 5 | 4 | |
| TRANSIENT ISCHAEMIC ATTACK | | | |
| subjects affected / exposed | 2 / 406 (0.49%) | 1 / 406 (0.25%) | |
| occurrences (all) | 3 | 1 | |
| TREMOR | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 6 / 406 (1.48%) | |
| occurrences (all) | 1 | 7 | |
| VASCULAR DEMENTIA | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 2 / 406 (0.49%) | |
| occurrences (all) | 0 | 2 | |
| VISUAL FIELD DEFECT | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences (all) | 0 | 1 | |
| Blood and lymphatic system disorders | | | |
| ANAEMIA | | | |
| subjects affected / exposed | 27 / 406 (6.65%) | 40 / 406 (9.85%) | |
| occurrences (all) | 34 | 66 | |
| BICYTOPENIA | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences (all) | 0 | 1 | |

| | | | |
|---|---|---|---|
| BONE MARROW FAILURE | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| COAGULOPATHY | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences (all) | 0 | 1 | |
| CYTOPENIA | | | |
| subjects affected / exposed | 4 / 406 (0.99%) | 4 / 406 (0.99%) | |
| occurrences (all) | 4 | 4 | |
| HAEMATOTOXICITY | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences (all) | 0 | 1 | |
| INCREASED TENDENCY TO BRUISE | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences (all) | 0 | 1 | |
| IRON DEFICIENCY ANAEMIA | | | |
| subjects affected / exposed | 4 / 406 (0.99%) | 3 / 406 (0.74%) | |
| occurrences (all) | 4 | 3 | |
| LEUKOCYTOSIS | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| LEUKOPENIA | | | |
| subjects affected / exposed | 3 / 406 (0.74%) | 3 / 406 (0.74%) | |
| occurrences (all) | 3 | 3 | |
| LYMPHADENITIS | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences (all) | 0 | 1 | |
| LYMPHADENOPATHY | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 9 / 406 (2.22%) | |
| occurrences (all) | 1 | 9 | |
| LYMPHOCYTOSIS | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences (all) | 0 | 1 | |
| NEUTROPENIA | | | |
| subjects affected / exposed | 37 / 406 (9.11%) | 49 / 406 (12.07%) | |
| occurrences (all) | 60 | 94 | |

| | | | |
|---|---|---|---|
| NEUTROPHILIA | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences (all) | 0 | 1 | |
| PANCYTOPENIA | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 2 / 406 (0.49%) | |
| occurrences (all) | 0 | 2 | |
| POLYCYTHAEMIA | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| SPLENIC INFARCTION | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences (all) | 0 | 1 | |
| SPLENOMEGALY | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| THROMBOCYTOPENIA | | | |
| subjects affected / exposed | 23 / 406 (5.67%) | 65 / 406 (16.01%) | |
| occurrences (all) | 28 | 106 | |
| THROMBOCYTOPENIC PURPURA | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences (all) | 0 | 1 | |
| THROMBOCYTOSIS | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Ear and labyrinth disorders | | | |
| DEAFNESS | | | |
| subjects affected / exposed | 2 / 406 (0.49%) | 2 / 406 (0.49%) | |
| occurrences (all) | 2 | 2 | |
| DEAFNESS UNILATERAL | | | |
| subjects affected / exposed | 3 / 406 (0.74%) | 1 / 406 (0.25%) | |
| occurrences (all) | 3 | 1 | |
| EAR CONGESTION | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| EAR DISCOMFORT | | | |

| | | | | |
|---|---|---|---|---|
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | | |
| occurrences (all) | 0 | 1 | | |
| EAR HAEMORRHAGE | | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | | |
| occurrences (all) | 0 | 1 | | |
| EAR PAIN | | | | |
| subjects affected / exposed | 5 / 406 (1.23%) | 5 / 406 (1.23%) | | |
| occurrences (all) | 5 | 5 | | |
| EXCESSIVE CERUMEN PRODUCTION | | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | | |
| occurrences (all) | 0 | 1 | | |
| EXTERNAL EAR PAIN | | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | | |
| occurrences (all) | 0 | 1 | | |
| HYPERACUSIS | | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | | |
| occurrences (all) | 1 | 0 | | |
| HYPOACUSIS | | | | |
| subjects affected / exposed | 2 / 406 (0.49%) | 1 / 406 (0.25%) | | |
| occurrences (all) | 2 | 1 | | |
| MENIERE'S DISEASE | | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | | |
| occurrences (all) | 0 | 1 | | |
| MIDDLE EAR DISORDER | | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | | |
| occurrences (all) | 1 | 0 | | |
| OTORRHOEA | | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 1 / 406 (0.25%) | | |
| occurrences (all) | 1 | 1 | | |
| TINNITUS | | | | |
| subjects affected / exposed | 4 / 406 (0.99%) | 8 / 406 (1.97%) | | |
| occurrences (all) | 4 | 8 | | |
| TYMPANIC MEMBRANE PERFORATION | | | | |
| subjects affected / exposed | 2 / 406 (0.49%) | 0 / 406 (0.00%) | | |
| occurrences (all) | 2 | 0 | | |

| | | | |
|---|---|---|---|
| VERTIGO | | | |
| subjects affected / exposed | 3 / 406 (0.74%) | 7 / 406 (1.72%) | |
| occurrences (all) | 3 | 8 | |
| VERTIGO POSITIONAL | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Eye disorders | | | |
| ANGLE CLOSURE GLAUCOMA | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences (all) | 0 | 1 | |
| ASTHENOPIA | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 1 / 406 (0.25%) | |
| occurrences (all) | 2 | 1 | |
| BLEPHARAL PIGMENTATION | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| BLEPHARITIS | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 1 / 406 (0.25%) | |
| occurrences (all) | 1 | 1 | |
| BLEPHAROSPASM | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 2 / 406 (0.49%) | |
| occurrences (all) | 1 | 2 | |
| BLINDNESS | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences (all) | 0 | 1 | |
| CATARACT | | | |
| subjects affected / exposed | 2 / 406 (0.49%) | 4 / 406 (0.99%) | |
| occurrences (all) | 2 | 4 | |
| CATARACT NUCLEAR | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| CONJUNCTIVAL HAEMORRHAGE | | | |
| subjects affected / exposed | 8 / 406 (1.97%) | 1 / 406 (0.25%) | |
| occurrences (all) | 8 | 1 | |
| CONJUNCTIVITIS ALLERGIC | | | |

| | | | | |
|---|---|---|---|---|
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | | |
| occurrences (all) | 0 | 1 | | |
| DIABETIC RETINOPATHY | | | | |
| subjects affected / exposed | 2 / 406 (0.49%) | 1 / 406 (0.25%) | | |
| occurrences (all) | 2 | 1 | | |
| DIPLOPIA | | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | | |
| occurrences (all) | 1 | 0 | | |
| DRY AGE-RELATED MACULAR DEGENERATION | | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | | |
| occurrences (all) | 0 | 1 | | |
| DRY EYE | | | | |
| subjects affected / exposed | 10 / 406 (2.46%) | 7 / 406 (1.72%) | | |
| occurrences (all) | 11 | 7 | | |
| ERYTHEMA OF EYELID | | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | | |
| occurrences (all) | 1 | 0 | | |
| EYE ALLERGY | | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 1 / 406 (0.25%) | | |
| occurrences (all) | 1 | 1 | | |
| EYE DISCHARGE | | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 2 / 406 (0.49%) | | |
| occurrences (all) | 1 | 3 | | |
| EYE HAEMORRHAGE | | | | |
| subjects affected / exposed | 4 / 406 (0.99%) | 1 / 406 (0.25%) | | |
| occurrences (all) | 5 | 1 | | |
| EYE INFLAMMATION | | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | | |
| occurrences (all) | 1 | 0 | | |
| EYE OEDEMA | | | | |
| subjects affected / exposed | 13 / 406 (3.20%) | 3 / 406 (0.74%) | | |
| occurrences (all) | 15 | 3 | | |
| EYE PAIN | | | | |
| subjects affected / exposed | 3 / 406 (0.74%) | 2 / 406 (0.49%) | | |
| occurrences (all) | 3 | 2 | | |

| | | | |
|---|---|---|---|
| EYE PRURITUS | | | |
| subjects affected / exposed | 2 / 406 (0.49%) | 1 / 406 (0.25%) | |
| occurrences (all) | 2 | 1 | |
| EYE SWELLING | | | |
| subjects affected / exposed | 36 / 406 (8.87%) | 8 / 406 (1.97%) | |
| occurrences (all) | 40 | 10 | |
| EYE ULCER | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences (all) | 0 | 1 | |
| EYELID OEDEMA | | | |
| subjects affected / exposed | 2 / 406 (0.49%) | 1 / 406 (0.25%) | |
| occurrences (all) | 3 | 1 | |
| GLAUCOMA | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 1 / 406 (0.25%) | |
| occurrences (all) | 1 | 1 | |
| IRITIS | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| KERATOCONUS | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences (all) | 0 | 1 | |
| LACRIMATION INCREASED | | | |
| subjects affected / exposed | 15 / 406 (3.69%) | 4 / 406 (0.99%) | |
| occurrences (all) | 15 | 4 | |
| MACULAR DEGENERATION | | | |
| subjects affected / exposed | 3 / 406 (0.74%) | 0 / 406 (0.00%) | |
| occurrences (all) | 3 | 0 | |
| MACULAR FIBROSIS | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences (all) | 0 | 1 | |
| MACULAR OEDEMA | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| OCULAR HYPERAEMIA | | | |
| subjects affected / exposed | 7 / 406 (1.72%) | 7 / 406 (1.72%) | |
| occurrences (all) | 11 | 7 | |

| | | | |
|---|---|---|---|
| OCULAR HYPERTENSION | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| ORBITAL OEDEMA | | | |
| subjects affected / exposed | 5 / 406 (1.23%) | 0 / 406 (0.00%) | |
| occurrences (all) | 5 | 0 | |
| PERIORBITAL OEDEMA | | | |
| subjects affected / exposed | 50 / 406 (12.32%) | 22 / 406 (5.42%) | |
| occurrences (all) | 58 | 28 | |
| PHOTOPHOBIA | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences (all) | 0 | 1 | |
| PHOTOPSIA | | | |
| subjects affected / exposed | 2 / 406 (0.49%) | 0 / 406 (0.00%) | |
| occurrences (all) | 2 | 0 | |
| RETINAL DETACHMENT | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 2 / 406 (0.49%) | |
| occurrences (all) | 0 | 2 | |
| RETINAL HAEMORRHAGE | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 4 / 406 (0.99%) | |
| occurrences (all) | 1 | 4 | |
| RETINOPATHY | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences (all) | 0 | 1 | |
| RETINOPATHY HYPERTENSIVE | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| SCLERAL HAEMORRHAGE | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences (all) | 0 | 1 | |
| SWOLLEN TEAR DUCT | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| VISION BLURRED | | | |
| subjects affected / exposed | 11 / 406 (2.71%) | 11 / 406 (2.71%) | |
| occurrences (all) | 13 | 13 | |

| | | | |
|---|---|---|---|
| VISUAL IMPAIRMENT | | | |
| subjects affected / exposed | 4 / 406 (0.99%) | 5 / 406 (1.23%) | |
| occurrences (all) | 4 | 7 | |
| VITREOUS FLOATERS | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 2 / 406 (0.49%) | |
| occurrences (all) | 1 | 2 | |
| VITREOUS HAEMORRHAGE | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences (all) | 0 | 1 | |
| Gastrointestinal disorders | | | |
| ABDOMINAL DISCOMFORT | | | |
| subjects affected / exposed | 14 / 406 (3.45%) | 13 / 406 (3.20%) | |
| occurrences (all) | 17 | 13 | |
| ABDOMINAL DISTENSION | | | |
| subjects affected / exposed | 10 / 406 (2.46%) | 11 / 406 (2.71%) | |
| occurrences (all) | 11 | 13 | |
| ABDOMINAL HERNIA | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences (all) | 0 | 1 | |
| ABDOMINAL PAIN | | | |
| subjects affected / exposed | 40 / 406 (9.85%) | 39 / 406 (9.61%) | |
| occurrences (all) | 42 | 45 | |
| ABDOMINAL PAIN UPPER | | | |
| subjects affected / exposed | 15 / 406 (3.69%) | 17 / 406 (4.19%) | |
| occurrences (all) | 16 | 18 | |
| ABDOMINAL PAIN LOWER | | | |
| subjects affected / exposed | 4 / 406 (0.99%) | 4 / 406 (0.99%) | |
| occurrences (all) | 4 | 4 | |
| ABDOMINAL TENDERNESS | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 2 / 406 (0.49%) | |
| occurrences (all) | 0 | 2 | |
| ANAL FISSURE | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 3 / 406 (0.74%) | |
| occurrences (all) | 1 | 3 | |
| ANAL FISTULA | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences (all) | 0 | 1 | |
| ANAL INCONTINENCE | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| ANAL POLYP | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| ANORECTAL DISCOMFORT | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| ASCITES | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences (all) | 0 | 1 | |
| BOWEL MOVEMENT IRREGULARITY | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| BUCCAL MUCOSAL ROUGHENING | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences (all) | 0 | 1 | |
| CHANGE OF BOWEL HABIT | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 1 / 406 (0.25%) | |
| occurrences (all) | 1 | 1 | |
| COLITIS | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 4 / 406 (0.99%) | |
| occurrences (all) | 0 | 4 | |
| CROHN'S DISEASE | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 1 / 406 (0.25%) | |
| occurrences (all) | 2 | 1 | |
| CONSTIPATION | | | |
| subjects affected / exposed | 22 / 406 (5.42%) | 54 / 406 (13.30%) | |
| occurrences (all) | 24 | 64 | |
| DENTAL CARIES | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences (all) | 0 | 1 | |
| DIARRHOEA | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 151 / 406 (37.19%) | 112 / 406 (27.59%) | |
| occurrences (all) | 204 | 160 | |
| DIVERTICULUM | | | |
| subjects affected / exposed | 2 / 406 (0.49%) | 2 / 406 (0.49%) | |
| occurrences (all) | 2 | 2 | |
| DRY MOUTH | | | |
| subjects affected / exposed | 4 / 406 (0.99%) | 2 / 406 (0.49%) | |
| occurrences (all) | 4 | 2 | |
| DUODENAL ULCER | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 2 / 406 (0.49%) | |
| occurrences (all) | 0 | 2 | |
| DYSPEPSIA | | | |
| subjects affected / exposed | 35 / 406 (8.62%) | 20 / 406 (4.93%) | |
| occurrences (all) | 43 | 24 | |
| DYSPHAGIA | | | |
| subjects affected / exposed | 2 / 406 (0.49%) | 5 / 406 (1.23%) | |
| occurrences (all) | 2 | 5 | |
| EPIGASTRIC DISCOMFORT | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 1 / 406 (0.25%) | |
| occurrences (all) | 1 | 1 | |
| FAECES DISCOLOURED | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 2 / 406 (0.49%) | |
| occurrences (all) | 1 | 2 | |
| FAECES SOFT | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| FLATULENCE | | | |
| subjects affected / exposed | 9 / 406 (2.22%) | 9 / 406 (2.22%) | |
| occurrences (all) | 10 | 9 | |
| FOOD POISONING | | | |
| subjects affected / exposed | 3 / 406 (0.74%) | 2 / 406 (0.49%) | |
| occurrences (all) | 3 | 2 | |
| FREQUENT BOWEL MOVEMENTS | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 2 / 406 (0.49%) | |
| occurrences (all) | 0 | 2 | |
| GASTRIC ANTRAL VASCULAR | | | |

| | | | |
|---|---|---|---|
| ECTASIA | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences (all) | 0 | 1 | |
| GASTRIC ULCER | | | |
| subjects affected / exposed | 2 / 406 (0.49%) | 0 / 406 (0.00%) | |
| occurrences (all) | 2 | 0 | |
| GASTRITIS | | | |
| subjects affected / exposed | 2 / 406 (0.49%) | 5 / 406 (1.23%) | |
| occurrences (all) | 2 | 5 | |
| GASTRITIS EROSIVE | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 2 / 406 (0.49%) | |
| occurrences (all) | 0 | 2 | |
| GASTRITIS HAEMORRHAGIC | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences (all) | 0 | 1 | |
| GASTROINTESTINAL DISORDER | | | |
| subjects affected / exposed | 5 / 406 (1.23%) | 1 / 406 (0.25%) | |
| occurrences (all) | 5 | 1 | |
| GASTROINTESTINAL HAEMORRHAGE | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| GASTROINTESTINAL INFLAMMATION | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences (all) | 0 | 1 | |
| GASTROOESOPHAGEAL REFLUX DISEASE | | | |
| subjects affected / exposed | 7 / 406 (1.72%) | 5 / 406 (1.23%) | |
| occurrences (all) | 8 | 5 | |
| GINGIVAL BLEEDING | | | |
| subjects affected / exposed | 4 / 406 (0.99%) | 2 / 406 (0.49%) | |
| occurrences (all) | 4 | 2 | |
| GINGIVAL PAIN | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 2 / 406 (0.49%) | |
| occurrences (all) | 1 | 2 | |
| GLOSSODYNIA | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 2 / 406 (0.49%) | 2 / 406 (0.49%) | |
| occurrences (all) | 2 | 2 | |
| HAEMATEMESIS | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences (all) | 0 | 1 | |
| HAEMATOCHEZIA | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 1 / 406 (0.25%) | |
| occurrences (all) | 1 | 1 | |
| HAEMORRHOIDAL HAEMORRHAGE | | | |
| subjects affected / exposed | 2 / 406 (0.49%) | 1 / 406 (0.25%) | |
| occurrences (all) | 2 | 1 | |
| HAEMORRHOIDS | | | |
| subjects affected / exposed | 4 / 406 (0.99%) | 7 / 406 (1.72%) | |
| occurrences (all) | 4 | 8 | |
| HIATUS HERNIA | | | |
| subjects affected / exposed | 4 / 406 (0.99%) | 2 / 406 (0.49%) | |
| occurrences (all) | 4 | 2 | |
| HYPERCHLORHYDRIA | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| ILEUS PARALYTIC | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| IRRITABLE BOWEL SYNDROME | | | |
| subjects affected / exposed | 2 / 406 (0.49%) | 1 / 406 (0.25%) | |
| occurrences (all) | 2 | 1 | |
| LARGE INTESTINE POLYP | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| LIP DRY | | | |
| subjects affected / exposed | 2 / 406 (0.49%) | 0 / 406 (0.00%) | |
| occurrences (all) | 2 | 0 | |
| LIP PAIN | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| LIP SWELLING | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 1 / 406 (0.25%) | 1 / 406 (0.25%) | |
| occurrences (all) | 1 | 1 | |
| MELAENA | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 1 / 406 (0.25%) | |
| occurrences (all) | 1 | 1 | |
| MOUTH CYST | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| MOUTH HAEMORRHAGE | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 3 / 406 (0.74%) | |
| occurrences (all) | 0 | 3 | |
| MOUTH ULCERATION | | | |
| subjects affected / exposed | 17 / 406 (4.19%) | 27 / 406 (6.65%) | |
| occurrences (all) | 17 | 40 | |
| NAUSEA | | | |
| subjects affected / exposed | 146 / 406 (35.96%) | 108 / 406 (26.60%) | |
| occurrences (all) | 180 | 125 | |
| ODYNOPHAGIA | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences (all) | 0 | 1 | |
| OESOPHAGITIS | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| ORAL MUCOSAL BLISTERING | | | |
| subjects affected / exposed | 3 / 406 (0.74%) | 0 / 406 (0.00%) | |
| occurrences (all) | 3 | 0 | |
| ORAL PAIN | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 4 / 406 (0.99%) | |
| occurrences (all) | 0 | 4 | |
| PAROTID GLAND ENLARGEMENT | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences (all) | 0 | 1 | |
| POUCHITIS | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| PROCTALGIA | | | |

| | | | | |
|---|---|---|---|---|
| subjects affected / exposed | 1 / 406 (0.25%) | 4 / 406 (0.99%) | | |
| occurrences (all) | 1 | 4 | | |
| RECTAL DISCHARGE | | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | | |
| occurrences (all) | 1 | 0 | | |
| RECTAL HAEMORRHAGE | | | | |
| subjects affected / exposed | 9 / 406 (2.22%) | 7 / 406 (1.72%) | | |
| occurrences (all) | 9 | 7 | | |
| RECTAL POLYP | | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 1 / 406 (0.25%) | | |
| occurrences (all) | 5 | 1 | | |
| REFLUX GASTRITIS | | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | | |
| occurrences (all) | 1 | 0 | | |
| RETCHING | | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | | |
| occurrences (all) | 0 | 1 | | |
| SPLENIC ARTERY ANEURYSM | | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | | |
| occurrences (all) | 0 | 1 | | |
| STOMATITIS | | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 3 / 406 (0.74%) | | |
| occurrences (all) | 1 | 3 | | |
| SWOLLEN TONGUE | | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 2 / 406 (0.49%) | | |
| occurrences (all) | 1 | 2 | | |
| TONGUE BLISTERING | | | | |
| subjects affected / exposed | 2 / 406 (0.49%) | 0 / 406 (0.00%) | | |
| occurrences (all) | 2 | 0 | | |
| TONGUE COATED | | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | | |
| occurrences (all) | 1 | 0 | | |
| TONGUE OEDEMA | | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | | |
| occurrences (all) | 1 | 0 | | |
| TONGUE ULCERATION | | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 2 / 406 (0.49%) | 0 / 406 (0.00%) | |
| occurrences (all) | 3 | 0 | |
| TOOTH DISORDER | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| TOOTH EROSION | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences (all) | 0 | 1 | |
| TOOTH IMPACTED | | | |
| subjects affected / exposed | 2 / 406 (0.49%) | 0 / 406 (0.00%) | |
| occurrences (all) | 2 | 0 | |
| TOOTH LOSS | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 1 / 406 (0.25%) | |
| occurrences (all) | 1 | 1 | |
| TOOTHACHE | | | |
| subjects affected / exposed | 3 / 406 (0.74%) | 7 / 406 (1.72%) | |
| occurrences (all) | 3 | 8 | |
| VOMITING | | | |
| subjects affected / exposed | 67 / 406 (16.50%) | 53 / 406 (13.05%) | |
| occurrences (all) | 81 | 64 | |
| UMBILICAL HERNIA | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences (all) | 0 | 1 | |
| Skin and subcutaneous tissue disorders | | | |
| ACNE | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 12 / 406 (2.96%) | |
| occurrences (all) | 0 | 13 | |
| ACTINIC KERATOSIS | | | |
| subjects affected / exposed | 2 / 406 (0.49%) | 1 / 406 (0.25%) | |
| occurrences (all) | 2 | 1 | |
| ALOPECIA | | | |
| subjects affected / exposed | 22 / 406 (5.42%) | 21 / 406 (5.17%) | |
| occurrences (all) | 23 | 21 | |
| BLISTER | | | |
| subjects affected / exposed | 3 / 406 (0.74%) | 2 / 406 (0.49%) | |
| occurrences (all) | 3 | 2 | |

| | | | |
|---|---|---|---|
| BLOOD BLISTER | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| COLD SWEAT | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 3 / 406 (0.74%) | |
| occurrences (all) | 0 | 3 | |
| DERMAL CYST | | | |
| subjects affected / exposed | 4 / 406 (0.99%) | 1 / 406 (0.25%) | |
| occurrences (all) | 4 | 1 | |
| DERMATITIS | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 1 / 406 (0.25%) | |
| occurrences (all) | 1 | 1 | |
| DERMATITIS ACNEIFORM | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 2 / 406 (0.49%) | |
| occurrences (all) | 0 | 3 | |
| DERMATITIS ALLERGIC | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences (all) | 0 | 1 | |
| DERMATITIS CONTACT | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| DERMATOSIS | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| DIABETIC FOOT | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences (all) | 0 | 1 | |
| DRY SKIN | | | |
| subjects affected / exposed | 21 / 406 (5.17%) | 21 / 406 (5.17%) | |
| occurrences (all) | 22 | 24 | |
| ECZEMA | | | |
| subjects affected / exposed | 7 / 406 (1.72%) | 8 / 406 (1.97%) | |
| occurrences (all) | 8 | 8 | |
| ERYTHEMA | | | |
| subjects affected / exposed | 5 / 406 (1.23%) | 7 / 406 (1.72%) | |
| occurrences (all) | 6 | 7 | |

| | | | | |
|---|---|---|---|---|
| ERYTHEMA NODOSUM | | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 1 / 406 (0.25%) | | |
| occurrences (all) | 1 | 1 | | |
| EXCESSIVE SKIN | | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | | |
| occurrences (all) | 1 | 0 | | |
| EXFOLIATIVE RASH | | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | | |
| occurrences (all) | 0 | 1 | | |
| FORDYCE SPOTS | | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | | |
| occurrences (all) | 0 | 1 | | |
| HAIR COLOUR CHANGES | | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | | |
| occurrences (all) | 0 | 1 | | |
| HAIR GROWTH ABNORMAL | | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 2 / 406 (0.49%) | | |
| occurrences (all) | 0 | 2 | | |
| HAND DERMATITIS | | | | |
| subjects affected / exposed | 2 / 406 (0.49%) | 0 / 406 (0.00%) | | |
| occurrences (all) | 2 | 0 | | |
| HYPERHIDROSIS | | | | |
| subjects affected / exposed | 6 / 406 (1.48%) | 13 / 406 (3.20%) | | |
| occurrences (all) | 6 | 13 | | |
| HYPERKERATOSIS | | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 2 / 406 (0.49%) | | |
| occurrences (all) | 0 | 2 | | |
| INGROWING NAIL | | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | | |
| occurrences (all) | 0 | 1 | | |
| INTERTRIGO | | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | | |
| occurrences (all) | 1 | 0 | | |
| LICHEN PLANUS | | | | |
| subjects affected / exposed | 3 / 406 (0.74%) | 0 / 406 (0.00%) | | |
| occurrences (all) | 3 | 0 | | |

| | | | |
|---|---|---|---|
| LICHEN SCLEROSUS | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| MILIARIA | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences (all) | 0 | 1 | |
| NAIL DISCOLOURATION | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 1 / 406 (0.25%) | |
| occurrences (all) | 1 | 1 | |
| NAIL RIDGING | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| NIGHT SWEATS | | | |
| subjects affected / exposed | 13 / 406 (3.20%) | 16 / 406 (3.94%) | |
| occurrences (all) | 13 | 16 | |
| ONYCHOCLASIS | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| ONYCHOMADESIS | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| PAIN OF SKIN | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 3 / 406 (0.74%) | |
| occurrences (all) | 1 | 3 | |
| PALMAR-PLANTAR ERYTHRODYSAESTHESIA SYNDROME | | | |
| subjects affected / exposed | 2 / 406 (0.49%) | 0 / 406 (0.00%) | |
| occurrences (all) | 2 | 0 | |
| PETECHIAE | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 1 / 406 (0.25%) | |
| occurrences (all) | 1 | 2 | |
| PHOTOSENSITIVITY REACTION | | | |
| subjects affected / exposed | 2 / 406 (0.49%) | 5 / 406 (1.23%) | |
| occurrences (all) | 2 | 6 | |
| PIGMENTATION DISORDER | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| PRURITUS | | | |
| subjects affected / exposed | 20 / 406 (4.93%) | 27 / 406 (6.65%) | |
| occurrences (all) | 23 | 30 | |
| PRURITUS GENERALISED | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences (all) | 0 | 1 | |
| PSORIASIS | | | |
| subjects affected / exposed | 2 / 406 (0.49%) | 5 / 406 (1.23%) | |
| occurrences (all) | 2 | 6 | |
| PURPURA | | | |
| subjects affected / exposed | 2 / 406 (0.49%) | 1 / 406 (0.25%) | |
| occurrences (all) | 2 | 1 | |
| RASH | | | |
| subjects affected / exposed | 77 / 406 (18.97%) | 119 / 406 (29.31%) | |
| occurrences (all) | 92 | 160 | |
| RASH ERYTHEMATOUS | | | |
| subjects affected / exposed | 6 / 406 (1.48%) | 4 / 406 (0.99%) | |
| occurrences (all) | 6 | 4 | |
| RASH FOLLICULAR | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 2 / 406 (0.49%) | |
| occurrences (all) | 0 | 2 | |
| RASH GENERALISED | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 3 / 406 (0.74%) | |
| occurrences (all) | 0 | 3 | |
| RASH MACULAR | | | |
| subjects affected / exposed | 2 / 406 (0.49%) | 2 / 406 (0.49%) | |
| occurrences (all) | 2 | 2 | |
| RASH MACULO-PAPULAR | | | |
| subjects affected / exposed | 4 / 406 (0.99%) | 11 / 406 (2.71%) | |
| occurrences (all) | 4 | 14 | |
| RASH PAPULAR | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 3 / 406 (0.74%) | |
| occurrences (all) | 1 | 3 | |
| RASH PRURITIC | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 5 / 406 (1.23%) | 6 / 406 (1.48%) | |
| occurrences (all) | 5 | 6 | |
| RASH VESICULAR | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 1 / 406 (0.25%) | |
| occurrences (all) | 1 | 1 | |
| ROSACEA | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 1 / 406 (0.25%) | |
| occurrences (all) | 1 | 1 | |
| SEBORRHOEA | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences (all) | 0 | 1 | |
| SKIN BURNING SENSATION | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences (all) | 0 | 1 | |
| SKIN DEPIGMENTATION | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 2 / 406 (0.49%) | |
| occurrences (all) | 1 | 2 | |
| SKIN DISORDER | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 1 / 406 (0.25%) | |
| occurrences (all) | 1 | 1 | |
| SKIN EXFOLIATION | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 4 / 406 (0.99%) | |
| occurrences (all) | 1 | 4 | |
| SKIN HYPERPIGMENTATION | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| SKIN HYPOPIGMENTATION | | | |
| subjects affected / exposed | 3 / 406 (0.74%) | 3 / 406 (0.74%) | |
| occurrences (all) | 3 | 3 | |
| SKIN IRRITATION | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 2 / 406 (0.49%) | |
| occurrences (all) | 1 | 2 | |
| SKIN LESION | | | |
| subjects affected / exposed | 5 / 406 (1.23%) | 7 / 406 (1.72%) | |
| occurrences (all) | 5 | 7 | |
| SKIN SENSITISATION | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 1 / 406 (0.25%) | 2 / 406 (0.49%) | |
| occurrences (all) | 1 | 2 | |
| SKIN STRIAE | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences (all) | 0 | 1 | |
| SKIN ULCER | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 2 / 406 (0.49%) | |
| occurrences (all) | 1 | 2 | |
| SWELLING FACE | | | |
| subjects affected / exposed | 9 / 406 (2.22%) | 3 / 406 (0.74%) | |
| occurrences (all) | 10 | 4 | |
| URTICARIA | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 2 / 406 (0.49%) | |
| occurrences (all) | 0 | 2 | |
| Renal and urinary disorders | | | |
| ACUTE KIDNEY INJURY | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences (all) | 0 | 1 | |
| BLADDER IRRITATION | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences (all) | 0 | 1 | |
| BLADDER SPASM | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| CALCULUS BLADDER | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences (all) | 0 | 1 | |
| CHRONIC KIDNEY DISEASE | | | |
| subjects affected / exposed | 3 / 406 (0.74%) | 1 / 406 (0.25%) | |
| occurrences (all) | 3 | 1 | |
| DYSURIA | | | |
| subjects affected / exposed | 2 / 406 (0.49%) | 3 / 406 (0.74%) | |
| occurrences (all) | 2 | 3 | |
| HAEMATURIA | | | |
| subjects affected / exposed | 4 / 406 (0.99%) | 4 / 406 (0.99%) | |
| occurrences (all) | 5 | 4 | |

| | | | |
|---|---|---|---|
| HYDRONEPHROSIS | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| NEPHROLITHIASIS | | | |
| subjects affected / exposed | 2 / 406 (0.49%) | 2 / 406 (0.49%) | |
| occurrences (all) | 3 | 2 | |
| NOCTURIA | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 4 / 406 (0.99%) | |
| occurrences (all) | 1 | 4 | |
| POLLAKIURIA | | | |
| subjects affected / exposed | 5 / 406 (1.23%) | 13 / 406 (3.20%) | |
| occurrences (all) | 5 | 14 | |
| POLYURIA | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 2 / 406 (0.49%) | |
| occurrences (all) | 0 | 2 | |
| PROTEINURIA | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 1 / 406 (0.25%) | |
| occurrences (all) | 1 | 1 | |
| RENAL CYST | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| RENAL IMPAIRMENT | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| RENAL PAIN | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences (all) | 0 | 1 | |
| URINARY INCONTINENCE | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 5 / 406 (1.23%) | |
| occurrences (all) | 1 | 5 | |
| URINARY RETENTION | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 2 / 406 (0.49%) | |
| occurrences (all) | 1 | 2 | |
| URINARY TRACT DISORDER | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences (all) | 0 | 1 | |

| | | | |
|---|---|---|---|
| URINE ODOUR ABNORMAL | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences (all) | 0 | 1 | |
| Endocrine disorders | | | |
| ADRENAL MASS | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| CUSHING'S SYNDROME | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| HYPERTHYROIDISM | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 1 / 406 (0.25%) | |
| occurrences (all) | 1 | 1 | |
| HYPOTHYROIDISM | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 7 / 406 (1.72%) | |
| occurrences (all) | 1 | 7 | |
| Musculoskeletal and connective tissue disorders | | | |
| ARTHRALGIA | | | |
| subjects affected / exposed | 71 / 406 (17.49%) | 66 / 406 (16.26%) | |
| occurrences (all) | 79 | 95 | |
| ARTHRITIS | | | |
| subjects affected / exposed | 3 / 406 (0.74%) | 6 / 406 (1.48%) | |
| occurrences (all) | 3 | 6 | |
| BACK PAIN | | | |
| subjects affected / exposed | 39 / 406 (9.61%) | 34 / 406 (8.37%) | |
| occurrences (all) | 43 | 39 | |
| BONE LOSS | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| BONE PAIN | | | |
| subjects affected / exposed | 22 / 406 (5.42%) | 9 / 406 (2.22%) | |
| occurrences (all) | 23 | 11 | |
| BURSITIS | | | |
| subjects affected / exposed | 2 / 406 (0.49%) | 1 / 406 (0.25%) | |
| occurrences (all) | 2 | 1 | |
| CHONDROCALCINOSIS | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences (all) | 0 | 1 | |
| CHONDROCALCINOSIS PYROPHOSPHATE | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences (all) | 0 | 1 | |
| FISTULA | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| FLANK PAIN | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 1 / 406 (0.25%) | |
| occurrences (all) | 1 | 1 | |
| FOOT DEFORMITY | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences (all) | 0 | 1 | |
| GROIN PAIN | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 2 / 406 (0.49%) | |
| occurrences (all) | 0 | 2 | |
| HAEMARTHROSIS | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| INCLUSION BODY MYOSITIS | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences (all) | 0 | 1 | |
| INTERVERTEBRAL DISC PROTRUSION | | | |
| subjects affected / exposed | 3 / 406 (0.74%) | 0 / 406 (0.00%) | |
| occurrences (all) | 3 | 0 | |
| JAW CYST | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| JOINT LOCK | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| JOINT STIFFNESS | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 1 / 406 (0.25%) | 4 / 406 (0.99%) | |
| occurrences (all) | 1 | 4 | |
| JOINT SWELLING | | | |
| subjects affected / exposed | 12 / 406 (2.96%) | 8 / 406 (1.97%) | |
| occurrences (all) | 12 | 8 | |
| MOBILITY DECREASED | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| MUSCLE SPASMS | | | |
| subjects affected / exposed | 134 / 406 (33.00%) | 14 / 406 (3.45%) | |
| occurrences (all) | 179 | 18 | |
| MUSCLE TWITCHING | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 2 / 406 (0.49%) | |
| occurrences (all) | 0 | 2 | |
| MUSCULAR WEAKNESS | | | |
| subjects affected / exposed | 4 / 406 (0.99%) | 3 / 406 (0.74%) | |
| occurrences (all) | 4 | 5 | |
| MUSCULOSKELETAL CHEST PAIN | | | |
| subjects affected / exposed | 3 / 406 (0.74%) | 6 / 406 (1.48%) | |
| occurrences (all) | 3 | 6 | |
| MUSCULOSKELETAL DISCOMFORT | | | |
| subjects affected / exposed | 3 / 406 (0.74%) | 2 / 406 (0.49%) | |
| occurrences (all) | 3 | 2 | |
| MUSCULOSKELETAL PAIN | | | |
| subjects affected / exposed | 25 / 406 (6.16%) | 22 / 406 (5.42%) | |
| occurrences (all) | 30 | 23 | |
| MUSCULOSKELETAL STIFFNESS | | | |
| subjects affected / exposed | 3 / 406 (0.74%) | 3 / 406 (0.74%) | |
| occurrences (all) | 3 | 3 | |
| MYALGIA | | | |
| subjects affected / exposed | 46 / 406 (11.33%) | 29 / 406 (7.14%) | |
| occurrences (all) | 53 | 32 | |
| NECK MASS | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 1 / 406 (0.25%) | |
| occurrences (all) | 1 | 1 | |
| NECK PAIN | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 7 / 406 (1.72%) | 9 / 406 (2.22%) | |
| occurrences (all) | 8 | 9 | |
| OSTEITIS DEFORMANS | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences (all) | 0 | 1 | |
| OSTEOARTHRITIS | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 2 / 406 (0.49%) | |
| occurrences (all) | 1 | 2 | |
| OSTEOPOROSIS | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 2 / 406 (0.49%) | |
| occurrences (all) | 1 | 2 | |
| PAIN IN EXTREMITY | | | |
| subjects affected / exposed | 53 / 406 (13.05%) | 42 / 406 (10.34%) | |
| occurrences (all) | 59 | 51 | |
| PAIN IN JAW | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 3 / 406 (0.74%) | |
| occurrences (all) | 1 | 3 | |
| PERIARTHRITIS | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 3 / 406 (0.74%) | |
| occurrences (all) | 0 | 3 | |
| PLANTAR FASCIITIS | | | |
| subjects affected / exposed | 2 / 406 (0.49%) | 2 / 406 (0.49%) | |
| occurrences (all) | 2 | 2 | |
| PLICA SYNDROME | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| RHABDOMYOLYSIS | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences (all) | 0 | 1 | |
| ROTATOR CUFF SYNDROME | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| SACROILIITIS | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences (all) | 0 | 1 | |
| SOFT TISSUE SWELLING | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences (all) | 0 | 1 | |
| SPINAL OSTEOARTHRITIS | | | |
| subjects affected / exposed | 2 / 406 (0.49%) | 0 / 406 (0.00%) | |
| occurrences (all) | 2 | 0 | |
| SPINAL PAIN | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| SYNOVIAL CYST | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| TEMPOROMANDIBULAR JOINT SYNDROME | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| TENDON PAIN | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences (all) | 0 | 1 | |
| TENDONITIS | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 2 / 406 (0.49%) | |
| occurrences (all) | 1 | 2 | |
| TRIGGER FINGER | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences (all) | 0 | 1 | |
| TRISMUS | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences (all) | 0 | 1 | |
| Infections and infestations | | | |
| ABDOMINAL INFECTION | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences (all) | 0 | 1 | |
| ABSCESS | | | |
| subjects affected / exposed | 2 / 406 (0.49%) | 0 / 406 (0.00%) | |
| occurrences (all) | 2 | 0 | |
| ANAL ABSCESS | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 406 (0.00%) | 2 / 406 (0.49%) | |
| occurrences (all) | 0 | 2 | |
| ANAL INFECTION | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences (all) | 0 | 1 | |
| ARTHRITIS BACTERIAL | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 2 / 406 (0.49%) | |
| occurrences (all) | 0 | 2 | |
| BODY TINEA | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences (all) | 0 | 1 | |
| BREAST CELLULITIS | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences (all) | 0 | 1 | |
| BRONCHITIS | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 4 / 406 (0.99%) | |
| occurrences (all) | 0 | 4 | |
| CAMPYLOBACTER INFECTION | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences (all) | 0 | 1 | |
| CANDIDA INFECTION | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 2 / 406 (0.49%) | |
| occurrences (all) | 1 | 2 | |
| CELLULITIS | | | |
| subjects affected / exposed | 8 / 406 (1.97%) | 9 / 406 (2.22%) | |
| occurrences (all) | 10 | 12 | |
| CLOSTRIDIUM DIFFICILE INFECTION | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 2 / 406 (0.49%) | |
| occurrences (all) | 1 | 2 | |
| CONJUNCTIVITIS | | | |
| subjects affected / exposed | 10 / 406 (2.46%) | 4 / 406 (0.99%) | |
| occurrences (all) | 12 | 4 | |
| CYSTITIS | | | |
| subjects affected / exposed | 2 / 406 (0.49%) | 1 / 406 (0.25%) | |
| occurrences (all) | 2 | 1 | |
| DIABETIC FOOT INFECTION | | | |

| | | | | |
|---|---|---|---|---|
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | | |
| occurrences (all) | 0 | 1 | | |
| EAR INFECTION | | | | |
| subjects affected / exposed | 13 / 406 (3.20%) | 11 / 406 (2.71%) | | |
| occurrences (all) | 15 | 12 | | |
| ENTERITIS INFECTIOUS | | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | | |
| occurrences (all) | 0 | 1 | | |
| ENTEROBIASIS | | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | | |
| occurrences (all) | 0 | 2 | | |
| EPIDIDYMITIS | | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 2 / 406 (0.49%) | | |
| occurrences (all) | 1 | 2 | | |
| ESCHERICHIA URINARY TRACT INFECTION | | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 1 / 406 (0.25%) | | |
| occurrences (all) | 1 | 1 | | |
| EYE INFECTION | | | | |
| subjects affected / exposed | 3 / 406 (0.74%) | 5 / 406 (1.23%) | | |
| occurrences (all) | 3 | 5 | | |
| EYE INFECTION VIRAL | | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | | |
| occurrences (all) | 0 | 1 | | |
| EYELID INFECTION | | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | | |
| occurrences (all) | 0 | 1 | | |
| FOLLICULITIS | | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 10 / 406 (2.46%) | | |
| occurrences (all) | 1 | 10 | | |
| FUNGAL INFECTION | | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 3 / 406 (0.74%) | | |
| occurrences (all) | 0 | 3 | | |
| FUNGAL SKIN INFECTION | | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 1 / 406 (0.25%) | | |
| occurrences (all) | 1 | 1 | | |

| | | | | |
|---|---|---|---|---|
| FURUNCLE | | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 1 / 406 (0.25%) | | |
| occurrences (all) | 1 | 1 | | |
| GASTROENTERITIS | | | | |
| subjects affected / exposed | 2 / 406 (0.49%) | 7 / 406 (1.72%) | | |
| occurrences (all) | 2 | 8 | | |
| GASTROENTERITIS NOROVIRUS | | | | |
| subjects affected / exposed | 3 / 406 (0.74%) | 2 / 406 (0.49%) | | |
| occurrences (all) | 3 | 2 | | |
| GASTROENTERITIS VIRAL | | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 1 / 406 (0.25%) | | |
| occurrences (all) | 1 | 1 | | |
| GASTROINTESTINAL VIRAL INFECTION | | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | | |
| occurrences (all) | 1 | 0 | | |
| GENITAL ABSCESS | | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | | |
| occurrences (all) | 1 | 0 | | |
| GINGIVITIS | | | | |
| subjects affected / exposed | 2 / 406 (0.49%) | 1 / 406 (0.25%) | | |
| occurrences (all) | 2 | 1 | | |
| GROIN ABSCESS | | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | | |
| occurrences (all) | 0 | 1 | | |
| HELICOBACTER INFECTION | | | | |
| subjects affected / exposed | 2 / 406 (0.49%) | 2 / 406 (0.49%) | | |
| occurrences (all) | 2 | 2 | | |
| HEPATITIS B | | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | | |
| occurrences (all) | 1 | 0 | | |
| HERPES OPHTHALMIC | | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | | |
| occurrences (all) | 0 | 1 | | |
| HERPES SIMPLEX | | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 1 / 406 (0.25%) | 2 / 406 (0.49%) | |
| occurrences (all) | 1 | 3 | |
| HERPES ZOSTER | | | |
| subjects affected / exposed | 10 / 406 (2.46%) | 7 / 406 (1.72%) | |
| occurrences (all) | 15 | 8 | |
| HORDEOLUM | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| INFECTED BITE | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences (all) | 0 | 1 | |
| INFECTED DERMAL CYST | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 1 / 406 (0.25%) | |
| occurrences (all) | 1 | 1 | |
| INFECTION | | | |
| subjects affected / exposed | 6 / 406 (1.48%) | 8 / 406 (1.97%) | |
| occurrences (all) | 6 | 8 | |
| INFECTIOUS MONONUCLEOSIS | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences (all) | 0 | 1 | |
| INFECTIVE GLOSSITIS | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| INFECTIVE KERATITIS | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| INFLUENZA | | | |
| subjects affected / exposed | 4 / 406 (0.99%) | 8 / 406 (1.97%) | |
| occurrences (all) | 4 | 8 | |
| INJECTION SITE INFECTION | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences (all) | 0 | 1 | |
| INTERVERTEBRAL DISCITIS | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences (all) | 0 | 2 | |
| KIDNEY INFECTION | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 1 / 406 (0.25%) | 1 / 406 (0.25%) | |
| occurrences (all) | 1 | 2 | |
| LABYRINTHITIS | | | |
| subjects affected / exposed | 3 / 406 (0.74%) | 6 / 406 (1.48%) | |
| occurrences (all) | 3 | 6 | |
| LOCALISED INFECTION | | | |
| subjects affected / exposed | 2 / 406 (0.49%) | 4 / 406 (0.99%) | |
| occurrences (all) | 2 | 4 | |
| LOWER RESPIRATORY TRACT INFECTION | | | |
| subjects affected / exposed | 55 / 406 (13.55%) | 68 / 406 (16.75%) | |
| occurrences (all) | 73 | 93 | |
| LUNG INFECTION | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 2 / 406 (0.49%) | |
| occurrences (all) | 0 | 2 | |
| LYMPH GLAND INFECTION | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| LYMPH NODE ABSCESS | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| MALARIA | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 2 / 406 (0.49%) | |
| occurrences (all) | 0 | 2 | |
| NAIL INFECTION | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences (all) | 0 | 1 | |
| NASOPHARYNGITIS | | | |
| subjects affected / exposed | 26 / 406 (6.40%) | 32 / 406 (7.88%) | |
| occurrences (all) | 34 | 39 | |
| ONYCHOMYCOSIS | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 2 / 406 (0.49%) | |
| occurrences (all) | 0 | 2 | |
| ORAL CANDIDIASIS | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 3 / 406 (0.74%) | |
| occurrences (all) | 1 | 3 | |

| | | | |
|---|---|---|---|
| ORAL FUNGAL INFECTION | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences (all) | 0 | 1 | |
| ORAL HERPES | | | |
| subjects affected / exposed | 6 / 406 (1.48%) | 13 / 406 (3.20%) | |
| occurrences (all) | 6 | 17 | |
| ORAL INFECTION | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 5 / 406 (1.23%) | |
| occurrences (all) | 1 | 5 | |
| OTITIS EXTERNA | | | |
| subjects affected / exposed | 3 / 406 (0.74%) | 1 / 406 (0.25%) | |
| occurrences (all) | 3 | 1 | |
| OTITIS MEDIA | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| OTITIS MEDIA ACUTE | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| PARONYCHIA | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences (all) | 0 | 1 | |
| PAROTITIS | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences (all) | 0 | 1 | |
| PHARYNGITIS | | | |
| subjects affected / exposed | 6 / 406 (1.48%) | 10 / 406 (2.46%) | |
| occurrences (all) | 6 | 10 | |
| PNEUMONIA | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 5 / 406 (1.23%) | |
| occurrences (all) | 1 | 5 | |
| POST PROCEDURAL INFECTION | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 1 / 406 (0.25%) | |
| occurrences (all) | 1 | 1 | |
| RASH PUSTULAR | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences (all) | 0 | 1 | |

| | | | |
|---|---|---|---|
| RESPIRATORY TRACT INFECTION | | | |
| subjects affected / exposed | 3 / 406 (0.74%) | 5 / 406 (1.23%) | |
| occurrences (all) | 3 | 5 | |
| RHINITIS | | | |
| subjects affected / exposed | 3 / 406 (0.74%) | 4 / 406 (0.99%) | |
| occurrences (all) | 3 | 4 | |
| RHINOVIRUS INFECTION | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| SEPSIS | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| SIALOADENITIS | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 2 / 406 (0.49%) | |
| occurrences (all) | 0 | 2 | |
| SINUSITIS | | | |
| subjects affected / exposed | 4 / 406 (0.99%) | 13 / 406 (3.20%) | |
| occurrences (all) | 4 | 14 | |
| SKIN CANDIDA | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences (all) | 0 | 1 | |
| SKIN INFECTION | | | |
| subjects affected / exposed | 4 / 406 (0.99%) | 2 / 406 (0.49%) | |
| occurrences (all) | 4 | 4 | |
| SOFT TISSUE INFECTION | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 3 / 406 (0.74%) | |
| occurrences (all) | 0 | 3 | |
| STAPHYLOCOCCAL INFECTION | | | |
| subjects affected / exposed | 2 / 406 (0.49%) | 0 / 406 (0.00%) | |
| occurrences (all) | 2 | 0 | |
| STREPTOCOCCAL INFECTION | | | |
| subjects affected / exposed | 3 / 406 (0.74%) | 0 / 406 (0.00%) | |
| occurrences (all) | 3 | 0 | |
| STRONGYLOIDIASIS | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | |
| occurrences (all) | 2 | 0 | |

| | | | | |
|---|---|---|---|---|
| TINEA CRURIS | | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | | |
| occurrences (all) | 1 | 0 | | |
| TINEA INFECTION | | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 2 / 406 (0.49%) | | |
| occurrences (all) | 1 | 2 | | |
| TINEA PEDIS | | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | | |
| occurrences (all) | 0 | 1 | | |
| TONSILLITIS | | | | |
| subjects affected / exposed | 3 / 406 (0.74%) | 2 / 406 (0.49%) | | |
| occurrences (all) | 3 | 2 | | |
| TOOTH ABSCESS | | | | |
| subjects affected / exposed | 4 / 406 (0.99%) | 11 / 406 (2.71%) | | |
| occurrences (all) | 4 | 11 | | |
| TOOTH INFECTION | | | | |
| subjects affected / exposed | 5 / 406 (1.23%) | 4 / 406 (0.99%) | | |
| occurrences (all) | 6 | 6 | | |
| UPPER RESPIRATORY TRACT INFECTION | | | | |
| subjects affected / exposed | 33 / 406 (8.13%) | 39 / 406 (9.61%) | | |
| occurrences (all) | 36 | 50 | | |
| URINARY TRACT INFECTION | | | | |
| subjects affected / exposed | 21 / 406 (5.17%) | 32 / 406 (7.88%) | | |
| occurrences (all) | 29 | 47 | | |
| VAGINAL INFECTION | | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | | |
| occurrences (all) | 1 | 0 | | |
| VARICELLA | | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | | |
| occurrences (all) | 1 | 0 | | |
| VIRAL INFECTION | | | | |
| subjects affected / exposed | 9 / 406 (2.22%) | 17 / 406 (4.19%) | | |
| occurrences (all) | 11 | 18 | | |
| VIRAL PHARYNGITIS | | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 2 / 406 (0.49%) | 1 / 406 (0.25%) | |
| occurrences (all) | 2 | 1 | |
| VIRAL RASH | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences (all) | 0 | 1 | |
| VIRAL UPPER RESPIRATORY TRACT INFECTION | | | |
| subjects affected / exposed | 2 / 406 (0.49%) | 3 / 406 (0.74%) | |
| occurrences (all) | 2 | 3 | |
| VULVOVAGINAL CANDIDIASIS | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 3 / 406 (0.74%) | |
| occurrences (all) | 0 | 3 | |
| WOUND INFECTION | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 1 / 406 (0.25%) | |
| occurrences (all) | 1 | 1 | |
| Metabolism and nutrition disorders | | | |
| ALCOHOL INTOLERANCE | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| DECREASED APPETITE | | | |
| subjects affected / exposed | 18 / 406 (4.43%) | 31 / 406 (7.64%) | |
| occurrences (all) | 21 | 34 | |
| DEHYDRATION | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 1 / 406 (0.25%) | |
| occurrences (all) | 1 | 1 | |
| DIABETES MELLITUS | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 2 / 406 (0.49%) | |
| occurrences (all) | 1 | 2 | |
| DIABETES MELLITUS INADEQUATE CONTROL | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences (all) | 0 | 1 | |
| FLUID RETENTION | | | |
| subjects affected / exposed | 16 / 406 (3.94%) | 14 / 406 (3.45%) | |
| occurrences (all) | 18 | 14 | |
| FOLATE DEFICIENCY | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences (all) | 0 | 1 | |
| FOOD INTOLERANCE | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences (all) | 0 | 1 | |
| GOUT | | | |
| subjects affected / exposed | 9 / 406 (2.22%) | 12 / 406 (2.96%) | |
| occurrences (all) | 12 | 14 | |
| HYPERCHOLESTEROLAEMIA | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 5 / 406 (1.23%) | |
| occurrences (all) | 0 | 5 | |
| HYPERKALAEMIA | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences (all) | 0 | 2 | |
| HYPERLIPIDAEMIA | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences (all) | 0 | 1 | |
| HYPERNATRAEMIA | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences (all) | 0 | 1 | |
| HYPERTRIGLYCERIDAEMIA | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences (all) | 0 | 1 | |
| HYPOCALCAEMIA | | | |
| subjects affected / exposed | 6 / 406 (1.48%) | 3 / 406 (0.74%) | |
| occurrences (all) | 6 | 7 | |
| HYPOGLYCAEMIA | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 3 / 406 (0.74%) | |
| occurrences (all) | 1 | 4 | |
| HYPOKALAEMIA | | | |
| subjects affected / exposed | 4 / 406 (0.99%) | 2 / 406 (0.49%) | |
| occurrences (all) | 8 | 2 | |
| HYPOMAGNESAEMIA | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences (all) | 0 | 1 | |
| HYPOPHOSPHATAEMIA | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 1 / 406 (0.25%) | 1 / 406 (0.25%) | |
| occurrences (all) | 14 | 1 | |
| INCREASED APPETITE | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences (all) | 0 | 1 | |
| IRON DEFICIENCY | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 3 / 406 (0.74%) | |
| occurrences (all) | 0 | 3 | |
| TETANY | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 0 / 406 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| TUMOUR LYSIS SYNDROME | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences (all) | 0 | 1 | |
| TYPE 2 DIABETES MELLITUS | | | |
| subjects affected / exposed | 0 / 406 (0.00%) | 1 / 406 (0.25%) | |
| occurrences (all) | 0 | 1 | |
| VITAMIN D DEFICIENCY | | | |
| subjects affected / exposed | 1 / 406 (0.25%) | 4 / 406 (0.99%) | |
| occurrences (all) | 1 | 4 | |

## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

| Date | Amendment |
|---|---|
| 08 June 2016 | The protocol was updated as regarding guidance on management of pleural effusions and the addition of concerns around pulmonary arterial hypertension. The requirement for bone marrow trephine was removed. For laboratory evaluations, LDH was changed to optional, lymphocyte count added and only one test for either AST or ALT was made acceptable. The definition of serious adverse events was updated to include new malignancies and CML disease progression. The section on study drug dose escalation was updated. Drug storage conditions and contraindications were updated to reflect the SmPC. Amendments also allowed GCSF to be given as a concomitant medication and advice regarding QT prolongation with TKIs was updated. The contact details for trials team, sponsor and central laboratory were updated. |
| 12 December 2016 | The protocol was updated to allow the use of generic imatinib, to remove the requirement for bone marrow aspirate samples, to correct SAE definitions and other typographical errors and inconsistencies. |

Notes:

### Interruptions (globally)

Were there any global interruptions to the trial? No

### Limitations and caveats

Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.

The additional endpoint of broad comparative costs between the regimens as described in the protocol, was not analysed at the end of study as there was no beneficial reason to do so when imatinib became generic in Dec 2016 at vastly reduced cost.

Notes: